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1 Summary  
Interleukin-7 (IL-7) is an essential and nonredundant cytokine required for the development 
and maintenance of mature T cell. Its availability is limited under normal conditions, but rises 
during lymphopenia, leading to increased T cell proliferation. The administration of 
recombinant IL-7 to normal or lymphopenic mice and humans results in increased T cell 
numbers and altered T cell phenotype. Hence, IL-7 administration could mediate therapeutic 
benefits in immunocompromised patients and is currently tested in several clinical trials, 
including anti-cancer trials. However, besides its well-studied effects on T cells little is known 
about the effect of IL-7 on other immune and non-immune cells and their influence on T cell 
homeostasis. Therefore, we evaluated the effect of IL-7 therapy on adoptively transferred T 
cells in IL-7 receptor (IL-7R)-competent and IL-7R-deficient lymphopenic mice. We confirm 
the benefits of IL-7 therapy on T cell responses but additionally show that many of these 
effects are dependent on IL-7R expression by host cells, indicating that IL-7R signaling in 
host cells modulates T cell responses. Surprisingly, peptide vaccination blunted the 
beneficial effect of IL-7 treatment on adoptive T cell therapy against cancer. Irrespective of 
peptide vaccination however, we show that efficient T cell responses against cancer are 
dependent on host IL-7R signaling. Based on studies in bone-marrow chimeric mice, we 
identify non-hematopoietic host cells as main regulators of IL-7 therapy-modulated T cell 
differentiation. We conclude from these data that IL-7 therapy affects non-hematopoietic 
stromal cells that modulate the success of adoptive T cell therapy. Our results confirm that 
stromal cells in various organs express il-7 and show that these cells are targeted by IL-7 
therapy in vivo. Hence, we propose that il-7-expressing cells regulate IL-7 therapy-modulated 
T cell homeostasis. To identify and study these il-7 expressing stromal cells in more detail, 
we characterized a new transgenic mouse model that will facilitate determining the molecular 
pathways to improve the success of adoptive T cell therapy. 
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2 Introduction 
Our interactions with the environment affect the quality of our lives, especially the period that 
we spend in health. Our body fights invaders with complex defense mechanisms, comprised 
of the outer physical layer of epithelial barriers and the inner motile cells of the immune 
system. The immune system can discriminate between normal - “healthy” and infected - 
“sick” cells by recognizing a variety of “danger cues”. When the immune system recognizes 
pathogen associated molecular patterns (PAMPs) or other foreign structures such as 
antigens (Ag) of pathogens, it responds. If the immune response is not strong enough, it 
leads to severe infection and disease. On the other hand, when the immune response is 
activated inappropriately strong or long, it causes immunopathology. Therefore, it is pivotal 
that each and every component of the immune response is tightly regulated. The immune 
system is comprised of various cell types and proteins that either circulate through the body 
or reside in particular tissues. All immune cell types are derived from the hematopoietic 
lineage, and each immune cell type plays a unique role in recognition of different hazardous 
factors, performing specialized functions and communicating with other cells. Based on their 
function, immune cells can be classified into two main arms, the innate and the adaptive 
immune cells (1). 
2.1 Innate immune system 
In general, innate immune cells recognize threats by their pattern recognition receptors 
(PRR) that bind PAMPs such as bacterial carbohydrates (e.g. lipopolysaccharide or 
mannose) and bacterial or viral nucleic acids (2). The main components of the innate 
immune system include the complement system, phagocytes and innate lymphoid cells 
(ILCs).  
The complement system is comprised of proteins that circulate in the blood stream in an 
inactive state. Upon triggering by pathogens, a chain reaction is set off and a cascade of 
proteins gets activated. These proteins directly kill bacteria or label them for better clearance 
by immune cells. In addition, they drive the innate immune response by attracting and 
activating phagocytes (3). 
Phagocytes ingest bacteria, viruses, dead and infected cells. Upon activation, they release 
proteins from their granules to help killing the invaders and to attract other immune cells. The 
population of phagocytes is very heterogeneous and includes neutrophils, macrophages and 
dendritic cells (DCs). Neutrophils belong to the early line of immune defense. Upon danger 
cues, they leave the bloodstream, trap, ingest and thus remove bacteria e.g. by release of 
net-like structures or by antimicrobial substances (4). Similarly, macrophages also clear 
invaders and damaged or dead cells. Moreover, they alert and attract other immune cells and 
can present Ags (5–8).  
Other members of the innate immune system are the functionally diverse group of innate 
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lymphoid cells (ILC). They include subsets that regulate lymphoid organ development, tissue 
homeostasis at mucosal surfaces but can also display antimicrobial activity (9). One of their 
members are natural killer (NK) cells. They recognize and kill virus-infected or mutated cells 
by releasing enzymes that e.g. perforate the target’s membrane. Besides, they express 
surface molecules that can trigger programmed cell death of infected or mutated cells (10). 
A small but functionally significant innate immune cell population consists of DCs. Immature 
DCs reside in tissues and take up pathogens or other foreign material by constantly sampling 
their surrounding with finger-like structures called dendrites. Upon activation through ligation 
of their PRRs immature DCs start to mature and migrate via the lymphatic system to local 
secondary lymphoid organs. The maturation changes their phenotype from a phagocytic cell 
to an Ag-presenting cell (APC) (11, 12). Ags are molecules that can stimulate lymphocytes 
by binding to T or B cell receptors (TCR or BCR). The TCR is restricted to recognize 
antigenic peptides only when bound to appropriate major histocompatibility complex (MHC) 
molecules. Maturing DCs upregulate MHC class I and II molecules as well as the expression 
of costimulatory surface molecules such as CD80/86 (cluster of differentiation 80/86). Higher 
surface MHC levels correlate with increased levels of Ag presentation. Additionally, CD80/86 
are ligands for the costimulatory receptor CD28 on T cells, thus allowing efficient Ag-
mediated T cell activation (13). Hence, activated DCs turn to the most powerful activators of 
the adaptive immune system. The different roles of activated adaptive immune cells will be 
described below. 
2.2 Adaptive immune system 
T and B lymphocytes form the adaptive immune system. Their response to threats that have 
not been eliminated by the innate immune system is delayed (14). Generally, adaptive 
immune responses are not induced at the site of infection but rather in secondary lymphoid 
organs (SLO) to which lymphocytes and APCs migrate (15). In SLOs, lymphocyte activation 
is mediated through specific Ag recognition by the appropriate TCR or BCR. Activated 
lymphocytes mediate highly specific responses and can memorize the Ag leading to faster 
and stronger reactivation upon reencounter (16). The ability of the adaptive immune system 
to provide a very specific protection against a broad range of pathogens requires an 
exceptionally diverse recognition capacity. Diversity is generated in early stages of 
development by random rearrangement of genes encoding for the BCR and TCR. To 
generate cells with receptors that recognize only foreign proteins, T and B cells have to 
undergo several selection processes. 
2.2.1 B cell development and function 
B cell development starts in the bone marrow and continues in peripheral lymphoid tissues 
such as the spleen. In the bone marrow, B cell development progresses through several 
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stages involving random gene rearrangements at the locus encoding the BCR, which result 
in the surface expression of a BCR capable of binding Ag. To avoid generation of B cells that 
target the own body, only those cells that did not encounter Ag during their maturation in the 
bone marrow can be activated after entry into the periphery (17). If B cells recognize an Ag in 
SLOs, they internalize and process it to present antigenic peptides via MHC-II molecules. 
CD4+ T cells recognizing such peptide-MHC-II complexes, get activated and provide help to 
further promote B cell activation. Then, B cells start to proliferate and develop into antibody- 
(Ab)-secreting plasma cells or long-lived memory B cells. Upon reencounter with the Ag, 
memory B cells can immediately mount a secondary response that provides an instant and 
high level of protection and thus the basis for vaccinations. For the development into such 
effective defense cells, activated B cells need to undergo several maturation processes, 
including somatic hypermutation. As a result of this process, mutations are introduced into 
the BCR gene and those B cells expressing a functionally improved BCR are positively 
selected. This affinity maturation ensures that highly effective BCRs are produced and 
released as cell-free Abs. Additionally, B cells undergo Ab class switching to produce Abs 
with different effector functions. For example, Abs can neutralize toxins or label infected cells 
for killing. Ab class switch is triggered by signals from T cells involving cytokine receptor and 
CD40 engagement on B cells (18). Other functions of T cells and their generation are 
described below. 
2.2.2 T cell development and function 
2.2.2.1 T cell development in the thymus 
Similar to B cells, T cell development also starts in the bone marrow. However, T cell 
progenitors leave the bone marrow and migrate into the thymus where they develop into 
thymocytes. During their development, thymocytes migrate through different stromal 
microenvironments called the thymic cortex and medulla where they receive unique signals 
that allow their maturation (Fig. 2.1). Early committed thymocytes lack expression of TCR 
and its coreceptors CD4 and CD8, and are therefore termed CD4/8 double-negative (DN) 
thymocytes. During the late DN stage, the TCR gene segments encoding the TCR-α and -β 
chain are recombined and an αβ-TCR first becomes expressed on the cell. This leads to 
proliferation and differentiation into the CD4 and CD8 double-positive (DP) stage. Then, 
thymocytes strongly interact with self-peptides presented by MHC-I and MHC-II molecules on 
cortical epithelial cells (cTECs). The interaction of the TCR with these self-peptide-MHC 
complexes determines the fate of the DP thymocytes. Too weak TCR signals result in death 
by neglect. Appropriate, intermediate signals lead to survival called positive selection. This 
process is accompanied by CD4 or CD8 lineage commitment. Then, CD4 and CD8 single-
positive (SP) thymocytes rapidly relocate to the medulla, where they scan DCs and 
medullary TECs (mTECs) for self-peptide-MHC ligands. Too strong TCR signaling promotes 
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cell death. This so-called negative selection ensures the elimination of potentially auto-
destructive T cells. Instead, the host provides just enough TCR-mediated stimulation by self-
peptide MHC-complexes to keep T cells alive (19). Ultimately, only about 5% of DP 
thymocytes survive selection and finally enter SLO as mature CD4+ T helper and CD8+ T 
killer cells (20, 21). 
 
Figure 2.1: T cell development is directed by interactions with stromal cells.  
T cell development proceeds along a well-ordered passage through different thymic stromal 
microenvironments. T cell progenitors enter the thymus through blood vessels near the 
junction of cortex and medulla. Early committed T cells, termed double-negative DN 
thymocytes can be further subdivided into four stages (DN1-4). At the DN3 stage, a TCR as 
well as CD4 and CD8 first become expressed on the cell surface. In the double-positive (DP) 
stage, the T cells scan self-peptide-MHC ligands presented by cortical epithelial cells 
(cTECs). Too weak TCR signaling results in death by neglect, whereas intermediate signals 
lead to survival and CD4 or CD8 lineage commitment. Then, CD4 or CD8 single positive 
(SP) thymocytes migrate to the medulla, where they bind to self-peptide-MHC ligands 
presented by DCs and medullary TECs (mTECs). Too strong TCR signaling promotes acute 
cell death. This negative selection ensures that T cells do not target the host and is known as 
central tolerance. (Adapted from Klein et al., 2009)  
 
2.2.2.2  T cell activation 
Once mature, naive CD4+ and CD8+ T cells circulate through the blood stream and lymphoid 
tissues until they are activated by encounter of their specific Ag presented by mature APCs 
in SLOs. The type of T cell response is dependent on the pathogen itself, the presentation of 
its Ags and the resulting inflammatory environment.  
Extracellular pathogens are ingested by professional APCs and digested by lysosomal 
enzymes. The resulting peptide fragments are presented to Ag-specific CD4+ T cells via 
MHC-II. Upon primary Ag contact, naive CD4+ T cells start to proliferate and differentiate into 
effector T cells that secrete multiple cytokines which help e.g. to activate the antimicrobial 
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properties of macrophages, provide support for CD8+ T cell responses and induce Ab 
production by B cells (1, 22). 
APCs process cytosolic pathogens as well as altered endogenous or viral proteins by the 
enzyme complex called proteasome and present resulting peptides via MHC-I molecules. 
Ags presented on MHC-I molecules activate naive Ag-specific CD8+ T cells. These cells 
proliferate and differentiate into cytotoxic T cells (CTL) that kill infected or mutated target 
cells and secrete pro-inflammatory cytokines. Activated T cells expand massively and 
acquire effector functions. The peak of the response is reached after 7-8 days resulting in 
maximal pathogen clearance. However, most effector cells die and only few cells survive to 
form a small but stable pool of memory T cells (23). Upon reencounter with their cognate Ag, 
memory CD8+ T cells exert effector functions within minutes (24). Hence, the generation of 
memory T cells ensures efficient and long-lasting protection against recurrent infections 
(Fig. 2.2).  
Figure 2.2: Ag-specific T cell response. 
The scheme of an acute immune response shows numbers of Ag-specific T cells (black line) 
at different stages after primary (Priming) and secondary Ag contact (Boosting). During the 
primary response, the fate of typical effector (red line) and memory (green line) T cells is 
shown. In addition, populations of intermediate longevity are depicted as purple and yellow 
lines. (Adapted from Jameson and Masopust, 2009) 
 
Yet, it is not completely clear how cell fate is determined and why some memory T cells live 
shorter and are less protective than others (25) (Fig. 2.2). Since this work is focused on the 
activation, expansion and anti-tumor function of CD8+ T cells under different experimental 
conditions, the factors influencing these processes will be discussed in more detail in the 
following section.  
The mere presentation of Ag, often referred to as “Signal 1”, is not sufficient to fully prime 
T cells and induce effector and memory cells. Costimulation (so-called “Signal 2”) needs to 
be provided simultaneously. This is delivered by ligation of T cell expressed CD28 to CD80 
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or CD86 expressed on the surface of APCs. Additionally, inflammatory cytokines including 
interleukin-12 (IL-12) and interferons (IFNs) promote CD8+ T cell expansion and act as 
“Signal 3” (Fig. 2.3A vs. 2.3B). These cytokines are released by innate immune cells in 
response to the pathogen (26–28). Interestingly, absence of IFN receptors on TCR-
transgenic T cells does not impede proliferation but survival of effector T cells (29). 
 
 
Figure 2.3: Signal 3 is required for efficient generation of CD8+ effector T cells. 
Maximal expansion, function, and survival of effector CD8+ T cells depend on the cytokine 
milieu during the early stages of the CD8+ T cell response. Several cytokines (IL-12, type I 
IFNs, and IFN-γ) can serve as Signal 3 in vitro. During an infection, the type of Signal 3 may 
mainly depend on the type of pathogen. (Adapted from Harty and Badovinac, 2008)  
 
CD4+ T cells also help to generate highly functional CD8+ effector T cells. They condition 
DCs via CD40 ligand-mediated signals to become more effective stimulators of CD8+ T cells 
(30–32). Fully activated CD8+ T cells start to proliferate and secrete cytokines like IL-2, IFN-γ 
as well as apoptosis-inducing tumor-necrosis factor (TNF). Importantly, they also release 
cytolytic mediators such as perforin and granzymes (Fig. 2.4). Most effector T cells 
downregulate the expression of the lymph node homing molecule L-Selectin (CD62L) and 
the α-chain of the cytokine receptor for IL-7 (IL-7Rα, CD127). The majority of effector T cells 
will die by apoptosis in the contraction phase, but some will give rise to long-lived, CD127-
expressing memory T cells (Fig. 2.4). 
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Figure 2.4: CD8+ T cell response to infection or vaccination.  
Upon activation of Ag-specific CD8+ T cells by antigenic peptides and co-stimulatory 
molecules presented by mature DCs, T cells proliferate and differentiate into effector T cells 
releasing cytokines. Most effector T cells loose expression of CD127 and CD62L and finally 
die. Many of the surviving memory precursor T cells express CD127. Upregulation of CD62L 
expression occurs in addition to other phenotypical changes that result in formation of 
memory T cells. A stable pool of memory T cells is maintained by a dynamic process 
comprised of slow proliferation (memory turnover) and cell death. (Adapted from Harty and 
Badovinac, 2008)  
 
Although the molecular mechanisms controlling contraction of Ag-specific CD8+ T cells are 
incompletely understood, it was shown that the onset and kinetics of CD8+ T cell contraction 
after Listeria monocytogenes and lymphocytic choriomeningitis virus infections are 
independent of dose and duration of the infection and amount of Ag displayed (33). 
Therefore it is assumed that contraction is “programmed” by early signals after infection 
independently of Ag clearance (28, 33). In proof-of-principle experiments using T cells with a 
mutated TCR-signaling domain, it was shown that qualitatively distinct TCR signals can 
separate effector from memory fates (34). The prevailing view that strong TCR ligation is 
required for inducing cytotoxic T cell responses and CD8+ T cell memory generation was 
challenged in 2009. It was reported that even very weak TCR-ligand interactions are 
sufficient to activate naive T cells, induce proliferation and promote formation of effector as 
well as memory cells in response to microbial infection. The strength of the TCR-ligand 
interaction determined only the size of the memory pool. Interestingly, these findings 
correlated with the fact that strongly stimulated T cells contracted and exited lymphoid 
organs later than weakly stimulated cells (35). However, the decisive pathways and 
environmental conditions required for efficient memory T cell development still remain largely 
elusive. 
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2.2.2.3 Formation of memory T cell subsets 
After contraction of the effector T cell population, a small pool of surviving memory CD8+ 
T cells containing diverse and convertible populations is maintained (Fig. 2.4). Two major 
subsets of memory cells were defined by the expression CD62L and chemokine (C-C motif) 
receptor 7 (CCR7). Effector-memory T cells (TEM) express low amounts of both molecules 
while central-memory T cells (TCM) express high amounts of CD62L and CCR7 (36). High 
expression of both molecules guides TCM into lymphoid tissues where they can self-renew. 
This process is termed homeostatic turnover (Fig 2.4). Compared to TCM, TEM rather reside in 
peripheral non-lymphoid tissues (37–40). How these two memory subsets develop and 
whether they are interconvertible has been actively debated in the literature for many years. 
Several models have been proposed to explain the divergent developmental fates of Ag-
experienced T cells (41). According to the “linear differentiation model”, most effector cells 
mature into terminally differentiated effector cells that finally die (39). However, some effector 
cells differentiate into TEM, which then convert into TCM, the population with self-renewal 
capacity (Fig. 2.5A). The “branching differentiation model” suggests that one activated T cell 
can give rise to progeny with distinct differentiation fates (Fig. 2.5B). Generation of 
heterogenic daughter cells might be achieved through mechanisms such as epigenetic 
changes or asymmetric cell division. In the latter case, the part of the cell distal to the APC-
contact-zone forms a daughter cell that gives rise to TCM while the part of cell including the 
APC-contact zone forms a daughter cell that gives rise to TEM (42). In the “self-renewing 
effector model”, activated T cells can develop into effector T cells or TCM that can self-renew 
(Fig. 2.5C) (43). These cells home to lymphoid tissues and undergo homeostatic turnover, 
but may also give rise to TEM that migrate to sites of infection and will finally die as terminally 
differentiated effector T cells. The branching and self-renewing effector models are partially 
questioned by lineage-tracing experiments demonstrating that memory responses are raised 
by cells that have already developed a full effector phenotype (44). In this context, it has also 
been proposed that very strong stimulation leads to terminally differentiated effector cells, 
which die during the contraction phase (45), whereas TCM preferentially develop from weakly 
activated T cells, which are e.g. recruited at later stages of the immune response and have 
superior survival capacities (‘‘latecomers’’) (46). Notably, the huge potential of T cells to 
adopt various fates was shown in two elegant studies in which a single adoptively transferred 
naive CD8+ T cells could give rise to effector as well as diverse memory populations (47, 48). 
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Figure 2.5: Models of memory T cell differentiation.  
(A) In the linear differentiation model, efficient activation of naive T cells results in generation 
of effector T cells, that die by apoptosis soon after pathogen clearance (senescent TEM), or 
differentiate into TEM that express low levels of CD62L, do not home to lymphoid tissues, and 
are replication incompetent. Yet, some TEM can give rise to TCM that express CD62L and are 
long-lived since they undergo homeostatic turnover in lymphoid tissues. (B) In the branched 
differentiation model it is proposed that one activated T cell can give rise to two daughter 
cells with different fates. (C) In the self-renewing effector model, it is suggested that a naive 
T cell can directly develop into a TCM or an effector T cell that can self-renew. (Adapted from 
Ahmed et al., 2009) 
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Besides the classical way of generating memory T cells in response to specific Ag contact, 
another pathogen-independent route exists in hosts with reduced numbers of lymphocytes 
(lymphopenia). Congenital genetic defects leading to the severe combined immunodeficiency 
syndrome or interventions like chemo- or radiotherapy can cause lymphopenia (49, 50). 
When only few or no T cells are present in a host, newly generated or adoptively transferred 
T cells undergo lymphopenia-induced proliferation (LIP). In this state, T cells divide at a slow 
rate in response to higher amounts of homeostatic cytokines and more frequent contact with 
low-affinity, self-Ag presented by APCs (51, 52). Thereby, under LIP, T cells gradually 
acquire characteristics of memory T cells (53). 
2.2.2.4 T cell differentiation and effector function 
The protective capacity of naive and memory T cells was assessed in several studies. They 
consistently showed that TM respond faster and more effectively at lower doses of Ag (54–
56). Whether TCM or TEM provide more protection against infections is still controversially 
discussed. It was reported that predominant generation of TEM correlated best with protection 
against Listeria monocytogenes (57). However, in another study it was demonstrated that 
TCM are more efficient in mediating protective immunity against lymphocytic choriomeningitis 
virus (39). In terms of adoptive T cell therapy, tumor-specific TCM cells showed increased 
anti-tumor activity compared to TEM cells (58, 59). Therefore, development of therapeutic 
strategies for the generation of large amounts of tumor-specific TCM are demanded to 
promote the success of adoptive T cell therapy against cancer. However, it is still unclear 
how differentiation and expansion of these T cells is regulated. As IL-7R-mediated signaling 
is involved in critical steps of naive and memory T cell development and homeostasis, a 
better understanding of this pathway may help to generate better therapeutic T cells (60). 
2.3 Regulation of CD8+ T cell homeostasis by IL-7R signaling 
2.3.1 Essential role of IL-7 signals for T cell generation and survival  
IL-7 was first described as growth factor for B cell progenitors in 1988 (61, 62). It is a highly 
homologous protein in mice and humans with a predicted size of 15 and 17 kDa, 
respectively. IL-7 is a non-classical interleukin, since it is mainly produced by non-immune 
cells such as fibroblasts and epithelial cells (63–66). The essential role of IL-7 signals for 
T cells was discovered in experiments with IL-7-deficient (IL-7-) mice, which contain only very 
few T cells (67). This defect is largely attributed to the lack of IL-7R signaling during very 
early stages of lymphocyte development such as in common lymphoid progenitors (CLP) and 
DN thymocytes (Fig. 2.6) (67, 68). However, the transfer of naive T cells from WT to IL-7- 
mice does not compensate for the developmental block suggesting that naive T cells are not 
able to survive in an IL-7- environment (69, 70). Recently, these findings were supported by 
elegant experiments using IL-7- mice with transgenic, thymus-specific il-7 expression. T cells 
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emigrating form the il-7 expressing thymus to the IL-7- periphery did not survive, showing that 
IL-7 is also needed for survival of mature T cells (71). By contrast, high levels of IL-7, as in 
IL-7-transgenic (-tg) mice or after IL-7 injections, dramatically raise the numbers of naive and 
memory T cells (72–76). Moreover, the overabundance of IL-7 in IL-7-tg mice leads to 
autoimmunity (77, 78). These results indicate that IL-7 availability must be tightly controlled 
for regulating immune responses. Furthermore, identifying regulators of IL-7 production but 
also of IL-7R expression is required in order to exploit its functions for immunotherapy. 
2.3.2 Regulation of IL-7R expression during T cell ontogeny 
The IL-7R is composed of the IL-7Rα-chain and the IL-2Rγ-chain, also known as common 
cytokine receptor γ-chain (γc-chain) (79). While the γc-chain is assumed to be expressed at 
constant levels by T cells (80, 81), the IL-7Rα is subjected to strong regulation throughout the 
T cell’s ontogeny (82). It is first induced on CLPs in the bone marrow (Fig. 2.6). Both, 
hematopoietic stem cells (HSCs) and CLP can probably generate early T cell lineage 
progenitors lacking IL-7Rα expression. In the following differentiation steps, the IL-7Rα is 
expressed on DN thymocytes promoting TCR gene rearrangement, then downregulated on 
DP thymocytes probably due to TCR signaling and finally reexpressed by SP thymocytes, 
which migrate to the periphery and form the naive T cell pool (75). Naive, mature T cells 
need signals from self-peptide-MHC complexes and IL-7 in order to survive (51, 83–85). 
Upon activation, most mature Ag-specific T cells lose the expression of IL-7Rα. Only a small 
population of effector T cells retains IL-7Rα on the surface, which marks, but not directs them 
to become memory T cells (86, 87). Memory T cell survival is dependent on less specific 
peptide-MHC interactions than naive T cells (88). While their basic turnover rate is rather 
dependent on IL-15R signals, IL-7R signaling promotes their survival (70, 89, 90). Increased 
levels of IL-7 together with more frequent contact to low-affinity self-Ag, as found under 
lymphopenic conditions, can even drive the proliferation of naive T cells that finally acquire a 
memory-like phenotype with similar characteristics as conventional TM (52, 70, 91).  
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Figure 2.6: Regulation of IL-7R expression during T cell development and maturation. 
(A) Developing T cells modulate the expression of IL-7R at various stages. This has 
consequences on TCR rearrangement, T cell survival and proliferation, as IL-7 signaling 
promotes all of these events. (B) In the periphery, mature naive and memory T cells express 
the IL-7R, but it is lost on most cells upon activation and differentiation to effector T cells. 
Besides, some innate lymphoid cells (ILCs) and distinct DC subsets also express IL-7Rα. 
IL-7 is produced by stromal cells including fibroblasts, endothelial cells and epithelial cells. 
(Adapted from Mackall et al., 2011b) 
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2.3.3 IL-7R signaling pathway in T cells 
On the molecular level, the IL-7R-associated signaling pathway involves two main signaling 
cascades, the PI3K (phosphoinositide 3-kinase) and the JAK-STAT (Janus kinase and signal 
transducer and activator of transcription) signaling cascade (Fig. 2.7A) (83, 92). The JAK-
STAT signaling pathway features JAK1, JAK3 and predominantly STAT5. IL-7R-mediated 
signaling upregulates the expression of the antiapoptotic molecule B cell lymphoma-2 (Bcl-2) 
and leads to reduced expression of CD62L as well as cyclin-dependent kinase inhibitor 1B 
(P27KIP1) via the inactivation of forkhead box O1 (FOXO1). Accordingly, IL-7R-mediated 
signaling regulates survival, migration and proliferation of T cells, respectively (93–95). In 
addition, it affects metabolism by increasing glucose uptake and by activating the energy-
sensitive kinase mammalian target of rapamycin (mTOR) which can induce proliferation and 
functional maturation during lymphopenia (96, 97).  
 
 
Figure 2.7: IL-7R signaling and its interplay with the TCR/CD8 complex. 
(A) The main IL-7R-signaling pathways through JAK1/3 and STAT5 or alternatively through 
PI3K and protein kinase B (PKB or AKT) are depicted. These two signaling pathways 
intersect, but the exact mechanism for this is unclear (dashed line). IL-7R-mediated signaling 
can induce downregulation of its own receptor through the inactivation of FOXO1. Main 
downstream target proteins of IL-7R ligation are involved in metabolism such as glucose 
transporter 1 (GLUT1) and mTOR, but also in migration such as CCR7 and CD62L. Further 
downstream targets regulate proliferation such as P27KIP1 and Bcl-2, Bcl-2-interacting 
mediator of cell death (BIM) and myeloid cell leukemia sequence 1 (MCL1). (B) IL-7R 
signaling causes upregulation of CD8α, which can enhance TCR/CD8 signaling. This may in 
turn block some IL-7R-mediated signals in a negative feedback loop. (Adapted from Takada 
and Jameson, 2009)  
 
Moreover, IL-7R signaling directly augments TCR-mediated signaling in at least two ways. 
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First, it causes reduced expression of the TCR signaling repressor Casitas B-lineage 
lymphoma B (Cbl-b) (98) and second, it leads to upregulation of the TCR-co-receptor CD8α 
(99). Together, this may increase TCR sensitivity, leading to stronger T cell responses 
against a threat or even self-Ag, thus inducing autoimmunity. In order to avoid excessive 
T cell activation, enhanced TCR signaling can in turn inhibit some IL-7R-mediated signals for 
maintaining TCR signaling thresholds. These include repression of CD8α and IL-7Rα 
upregulation (Fig. 2.7B). In another negative feedback loop, signaling through the IL-7R itself 
leads to IL-7Rα downmodulation directly by internalization and indirectly by transcriptional 
repression through the inactivation of FOXO1. This feedback may help to maximize the 
number of T cells that can survive with limiting amounts of IL-7 (81, 100, 101). However, 
recently is was shown that IL-7 signaling must be intermittent, not continuous, to promote 
CD8+ T cell survival instead of cell death (102). Using IL-7R-tg T cells constantly expressing 
the IL-7Rα, it was observed that continuous IL-7 supply induced naive CD8+ T cells to 
proliferate, acquire memory markers and produce IFN-γ, which finally lead to IFN-γ-triggered 
cell death. This indicates that downregulation of the IL-7R is not an altruistic feature of T cells 
to maximize overall T cell numbers, but rather helps T cells to adjust TCR stimulation 
thresholds. Also other cytokines have been shown to regulate IL-7Rα expression at least 
in vitro. IL-4, IL-6 and IL-15 decrease IL-7Rα expression on T cells, whereas TNF-α 
increases it (81). The mechanisms and in vivo relevance of these findings remain largely 
unclear, but may play crucial roles during T cell development and activation, where strong 
regulation of IL-7Rα expression can be observed (103). In summary, IL-7R-mediated 
signaling crucially regulates T cell survival and activation. Consequently therapeutic 
manipulation of this pathway may help to treat immunologic disorders. 
2.4 Role of IL-7R signaling in non-T cells 
Besides T cells, B-cell progenitors, ILCs, and DC subsets express the IL-7R (Fig. 2.6). While 
migratory DCs isolated from lymph nodes (LNs) express the IL-7R, it is absent from 
conventional and plasmacytoid DCs in spleen and LNs. Surprisingly, the frequency of 
migratory DCs remains unaffected by high amounts of IL-7 as found in IL-7tg mice. In 
contrast, the frequency of conventional and plasmacytoid DCs increased in those mice (104). 
With the help of mixed bone marrow (BM) transfer experiments, it has been shown that DC 
generation from IL-7R- BM is less efficient than from IL-7R+ BM. DCs are generated from 
common lymphoid and myeloid progenitors. Since reduced numbers of CLPs are found in 
IL-7- mice, the authors concluded that lymphoid DC generation is affected by the lack of IL-7 
early in development. The number of DCs is not only important for T cell activation but also 
for controlling T cell responsiveness to Ag (105). Hence, it remains to be determined whether 
exogenous IL-7 treatment may support T cell therapy indirectly via effects on DC numbers. 
IL-7 was also shown to act as chemoattractant factor on IL-7R+ monocytes isolated from 
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patients with rheumatoid arthritis (106). However myeloid cell numbers are not affected in 
IL-7R- mice and lineage tracing experiments could only identify few granulocytes that 
expressed IL-7R during their ontogeny (104, 107). Hence, the role of IL-7R signaling in 
myeloid cells remains elusive. Another hematopoietic population expressing the IL-7R are 
lymphoid tissue inducer (LTi) cells. They initiate development of lymphoid tissues by 
instructing mesenchymal cells (108, 109). In the absence of IL-7R signaling, the numbers of 
LTi cells and their expression of lymphotoxin are reduced. This correlates with the lack of 
lymphoid structures called Peyer’s patches in the intestine of IL-7R- mice (110, 111). Along 
this line, the majority of LNs are affected but present in IL-7R- animals (112). Concordantly, 
in mice overexpressing IL-7, the survival of LTi cells is prolonged and those mice have 
increased numbers of Peyer’s patches and multiple ectopic LNs (113). As LTi cells are 
needed for SLO repair after infection with LN stroma-targeting pathogens, LTi cells can also 
exert immunoregulatory properties in adult hosts (114). LTi cells belong to the 
heterogeneous group of ILCs. Other IL-7R+ members of this family can be found e.g. in the 
intestine, where they regulate the epithelial barrier function, thereby reducing microbe entry 
into the host and inflammatory responses (115–117). Since the inflammatory state can alter 
T cell responses, it is conceivable that IL-7 therapy modulates T cell responses indirectly via 
IL-7R+ ILCs. Recent studies provide evidence that the IL-7R is also expressed on lymphoid 
endothelial cells (118). This may affect Ag-transport to LNs and hence initiation of immune 
responses. Notably, IL-7R expression has been identified on carcinoma samples from breast 
and lung tumors (119). Consequently, in case of cancer patients, the therapeutic benefit of 
IL-7 administration needs to be determined individually in order to exclude potential pro-
survival effects on these tumor cells.  
2.5 Therapeutic manipulation of IL-7R signaling 
Recently, polymorphisms in the IL-7R gene have been identified as risk factor for a number 
of diseases that involve autoimmunity or excessive inflammatory responses including 
multiple sclerosis, type 1 diabetes, rheumatoid arthritis and inflammatory bowel disease 
(120). In mouse models, transgenic overexpression of il-7 or exogenous IL-7 administration 
were shown to induce autoimmune diseases like dermatitis and colitis or aggravate arthritis 
and induce bone loss, respectively (121–123). Attempts to inhibit IL-7R signaling with Abs 
led to reduced progression of rheumatoid arthritis in mice (106) and could even reverse the 
autoimmune phenotype in diabetes-prone mice (124, 125). The therapeutic success of IL-7R 
blockade was associated with long-term inhibition of T cell function as shown by low IFN-γ 
production and high expression of the proapoptotic cell surface molecule PD-1 (Programmed 
Death-1). Besides, it was also suggested that the local reduction of IL-7 production from the 
liver attenuated systemic T cell responses (126). On the other hand, several preclinical trials 
studying syndromes of immunodeficiency demonstrated beneficial effects of exogenous IL-7 
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administration on T cell immunity. In more detail, IL-7 therapy accelerated immune 
reconstitution after BM transplantation in mice and humans (127, 128), which helps to 
prevent infections in the immunocompromised hosts. IL-7 therapy also improved survival of 
mice during sepsis by elevating T cell numbers and function, therefore preventing 
immunoparalysis (129). Furthermore, preclinical trials showed that IL-7 therapy leads to 
enhanced T cell responses against viral infections and tumors, hence prolonged survival of 
the affected hosts. In addition, IL-7 therapy promoted production of cytoprotective IL-22, 
which counterbalanced organ pathology during chronic viral infection (98, 130–133). These 
and other findings indicated that IL-7 administration can be applied in a multitude of 
therapeutic settings and paved the way to first phase-I clinical trials. Evaluation of toxicity 
and biological activity of recombinant human IL-7 did not reveal any major adverse effects of 
the 14-days treatment over the observation period of 60 days (134). This was only the first 
step towards broad clinical use. The optimal schedule for IL-7 therapy needs to be further 
defined. Since TCR signaling leads to a transient downregulation of IL-7Rα expression, it is 
assumed that T cells are insensitive to IL-7 during the expansion and effector phase but 
react to IL-7 in the contraction and memory phase (70). Indeed, IL-7 treatment during the 
contraction phase of an anti-viral immune response, but not in the effector phase, could 
increase the number of surviving pathogen-specific CD8+ T cells for at least 2 months after 
infection (132). In current protocols for adoptive T cell therapy (ATT) of cancer, therapeutic T 
cells are genetically modified in order equip them with a tumor-specific TCR. Alternatively 
tumor-specific T cells are identified and expanded to large quantities in vitro. In both 
approaches, T cells are activated and cultivated for prolonged times in vitro, which can impair 
their long-term survival capacities (135). Here, IL-7 may be of use in vitro and in vivo to 
improve therapeutic T cell survival.  
In light of the vast therapeutic potential of IL-7 administration for reconstitution of 
immunodeficiency states (caused by e.g. human immunodeficiency virus, radio- or 
chemotherapy) and enhancement of immune function (e.g. to pathogens or cancer), it is 
crucial to determine the appropriate conditions where manipulation of the IL-7R signaling 
improves immunity while minimizing side effects. Here we asked whether, under 
lymphopenic conditions, IL-7 therapy enhances the success of ATT and whether additional 
peptide vaccination improves therapeutic outcome. Furthermore, we aimed to determine 
which other host cell types that control CD8+ T cell responses are responsive to IL-7 therapy. 
We asked whether IL-7 signaling in host cells affects CD8+ T cell responses under 
physiologic conditions and after IL-7 therapy. Therefore, we compared the differentiation and 
function of adoptively transferred CD8+ T cells in IL-7R signaling-competent and -deficient 
hosts. First evidence indicated that IL-7R signaling in host cells affects il-7 expression (91).
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Therefore, we studied which cells express il-7 and whether IL-7 therapy can affect their il-7 
production. 
3 Results 
3.1 Distribution and regulation of il-7 gene expression 
Since the current methods to elucidate il-7 gene regulation in vivo are limiting, a novel IL-7-
reporter mouse was generated. It enables the non-invasive quantification of il-7 gene activity 
and simultaneous targeting of genes in il-7-expressing cells (63). The generation of this 
mouse was based on the bacterial artificial chromosome (BAC) transgenic technology (136). 
The full length il-7 promoter from the BAC RP23-446B12 was used to control the expression 
of the cDNAs encoding for enhanced green fluorescent protein (eGFP, G), improved Cre 
recombinase (C), human diphteria toxin receptor (D) and the click beetle green 
luciferase 99 (L). Hence, the construct was termed IL-7GCDL. In order to achieve 
comparable translation of the GCDL-cDNAs, they were linked by nucleotide sequences 
encoding the P2A peptide that dissociate by self-cleavage during translation (137). Two 
transgenic mouse lines were established, hereafter referred to as IL-7GCDL line A and line 
B. The levels of endogenous il-7 mRNA expression correlate with luciferase signals 
determined by bioluminescence (BL) in vivo imaging, which strongly indicates that the 
transgenic luciferase signal serves as faithful reporter of il-7 expression (63).  
When both reporter mouse lines were compared for the intensity of luciferase expression by 
in vivo imaging, higher total body BL signals were detected from the IL-7GCDL line A 
compared to line B, but the pattern of the BL signal was similar (Fig. 3.1A left, 3.1B). This 
suggests that more copies of the IL-7GCDL transgene were incorporated into the genome of 
line A compared to line B. In line with this, BL imaging of the isolated tissues revealed higher 
BL signals from most organs of line A compared to line B, but again the pattern of BL 
expression was comparable in both lines and correlated with il-7 expression by the 
respective tissues (Fig. 3.1A right, 3.1C) and (63). As expected, very high IL-7 reporter 
activity was detected in thymus. Surprisingly, similarly high BL levels were also recorded 
from the small and large intestine (SI and LI). Remarkably, the BL signal intensity reflects the 
total amount of IL-7 produced by the respective tissue. This implies that bigger sized tissues 
with a lower level of IL-7 expression per cell, such as the SI, can yield similar BL signals than 
small tissues with high levels of IL-7 expression per cell, such as the thymus or colon (Fig. 
3.1A right, 3.1C). Hence, BL signals reflect the relative contribution of different tissues to the 
overall production of IL-7 by the organism. Moreover, strong BL signals were detected in skin 
and lung. Lymph nodes emitted lower BL signals, than thymus and gastrointestinal tract. 
Spleen, liver and kidney yielded low BL signals. 
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Figure 3.1: IL-7GCDL mouse line A shows higher IL-7 reporter activity than line B.  
Luciferase expression of the IL-7GCDL mouse serves as reporter for il-7 gene expression. 
To determine luciferase transgene expression, B6 mice (WT) and IL-7GCDL mouse lines A 
and B were injected i.v. with 3 mg luciferin, anesthesized by isoflurane inhalation and (A left, 
B) mean body bioluminescence (BL) was measured. (A right, C) Tissues from these mice 
were collected, shortly incubated in PBS containing 1,5 mg/ml luciferin and organ BL was 
determined. Data are presented as (B) single dot/mouse and (C) mean of organs ± SEM 
from one representative experiment of 2 (n=4-8 reporter mice/group). Statistical analysis of 
data from body and organ BL intensities revealed significantly higher BL signals from 
IL-7GCDL line A than B (p<0,01; 1 and 2-way Anova). 
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The IL-7GCDL-transgene was integrated randomly into the genome and may therefore 
interfere with normal gene function. In order to test whether transgenesis affected immune 
cell development, splenic T and B cell numbers were determined for both IL-7GCDL lines. 
Splenic T and B cell numbers were not altered in IL-7GCDL line A and B compared to wild-
type (WT) mice (Fig. 3.2).  
 
Figure 3.2: Peripheral T and B cell numbers are normal in IL-7GCDL mice.  
Single cell suspensions from spleens of WT and both IL-7GCDL founder lines A and B were 
analyzed by flow cytometry. (A) Representative relative fluorescence intensities of the 
indicated markers to identify CD3+CD4+ and CD3+CD8+ T cells and CD19+IgM+ B cells are 
shown. Numbers indicate percentages of double positive cells. (B) Numbers are shown for 
the respective cell types in spleen as mean values ± SD (n=3 per group).  
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In addition, thymic T cell development in IL-7GCDL mice did not differ from WT mice as 
judged by a normal expression pattern of CD4 and CD8 T cell co-receptors (Fig. 3.3A, C). 
Moreover B and myeloid cell numbers were normal in the BM of IL-7GCDL compared to WT 
mice (Fig. 3.3B, D).  
 
Figure 3.3: Thymocyte, B and myeloid cell development is normal in IL-7GCDL mice.  
Single cell suspensions from (A) thymi and (B) bone marrow of WT and both IL-7GCDL 
founder lines A and B were analyzed by flow cytometry. (A-B) Relative fluorescence 
intensities for the indicated markers are shown. Numbers indicate percentages of the 
respective populations. Cell numbers of (C) CD4-CD8- double-negative (DN), CD4+CD8+ 
double-positive (DP), CD4+ and CD8+ single-positive (SP) cells per thymus as well as (D) 
CD19+IgM+ B cells and CD11b+ myeloid cells in bone marrow are shown as mean values ± 
SD (n=3 per group). 
 
 
Results 
 25 
Identification of IL-7-producing cells in tissues is impeded by the low level of IL-7 expression 
and the absence of reliable Abs for detecting it (64). In order to circumvent this issue, we 
made use of the il-7 promoter-driven Cre-transgene expression of the IL-7CGDL mouse. We 
crossed it to the loxP-Tag mouse, which expresses the oncogenic simian virus 40 (SV40) 
large T antigen (Tag) after Cre-mediated excision of a loxP-site flanked DNA stop cassette 
(138). In IL-7GCDLxloxP-Tag (Tag+) mice, Tag is detectable in il-7-expressing cells and 
leads to their expansion, facilitating the detection of these rare cell types.  
Tag+ mice were analyzed at 2-3 months of age. Necropsy revealed strongly enlarged thymi 
in 95 % of mice (n=20). Additionally, LNs were mildly enlarged and pancreas showed 
abnormal solid consistency in most Tag+ animals, whereas other tissues including lung, liver, 
intestine, skin, heart and kidney showed no gross signs of transformation (data not shown). 
In vivo BL imaging revealed that BL signals were strongly increased in the thorax of Tag+ 
mice (Fig. 3.4A) correlating with enlarged thymi (Fig. 3.4A inset). Flow cytometric analysis 
showed a more than 10-fold higher abundance of stroma cells (CD45-) in thymi of Tag+ mice, 
including epithelial cells (CD45-EpCam+) (Fig. 3.4B).  
Tissue sections revealed the colocalization of Tag protein and EpCam in certain areas of 
thymi from Tag+ mice. This demonstrates the expression of il-7 by thymic epithelial cells 
(TECs, Fig. 3.4C left). Interestingly, Tag+Epcam+ cells formed ring-like structures, which is in 
line with the transforming potential of the oncogene. Notably, not all Epcam+ cells expressed 
SV40 Tag, indicating that the il-7 promoter is not equally active in all TECs. On the other 
hand, many Tag+ cells did not express Epcam, indicating that non-epithelial cells also 
express il-7. These cells had a different morphology and some of them co-expressed gp38 
(38 kDa glycoprotein, also known as podoplanin), a protein that is highly expressed by 
fibroblasts, subsets of endothelial and some epithelial cells (139, 140) (Fig. 3.4C right).  
Tag expression is sufficient to immortalize cells for prolonged in vitro culture (141). To 
establish IL-7 reporter cell lines, tissues from Tag+ mice were enzymatically digested and the 
single cell suspension was cultivated. Cell cultures were generated from thymus, LNs, lung, 
pancreas, tongue and kidney. However, long-term cultures from colon, BM and spleen could 
not be established. All of the long-term cultivated cells expressed Tag, indicating that they or 
their progenitors have expressed il-7. These cells did not express the leukocyte specific 
molecule CD45, but contained different amounts of gp38-expressing cells, which indicates 
that the cultures consisted of stromal cells. It also implies that stromal cells from various 
immune and non-immune system-related tissues like LN and pancreas can produce IL-7 
(Fig. 3.4D).  
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Figure 3.4: IL-7-Cre-mediated ongogene activation leads to expansion of thymic 
stromal cells.  
(A) To assess luciferase transgene expression, IL-7GCDL and IL-7GCDLxloxP-Tag mice 
were injected i.v. with 3 mg luciferin and bioluminescence (BL) was measured. 
Representative BL intensities (BLI) for 6-8 week-old Tag- and Tag+ IL-7GCDL mice (Tag+, 
n=10) are shown in photons/s/cm2/steridian. Thymi of Tag+ mice are hyperplastic (inset). (B) 
Thymi of WT (Tag-) and Tag+ mice were enzymatically digested and analyzed by flow 
cytometry for the relative abundance of CD45- thymic stroma containing epithelial cells 
(CD45-EpCam+). Representative plots of 3 independent experiments are shown. (C) Thymi of 
Tag+ mice were analyzed by immunostaining for Tag, EpCam and gp38. Stainings of one out 
of 3 thymi are shown. (D) Cell cultures were established from the indicated organs of Tag+ 
mice and analyzed for the expression of Tag, CD45 and gp38 by flow cytometry. Data from 
one experiment are shown.  
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To enable analysis of il-7 gene regulation in distinct cell types, we aimed to generate 
epithelial and fibroblast-based IL-7 reporter lines. As our results (Fig. 3.4C) and previously 
published data indicate il-7 expression by thymic fibroblasts and TECs (66, 142), thymic 
stroma from Tag+ mice was chosen as source of both cell types. To enrich for epithelial cells 
over fibroblasts, epithelial cell growth factor, transferrin and insulin were added to the culture 
medium. Cells were cloned using limiting dilution. Flow cytometric analysis showed 
expression of Tag in all cultured cells (Fig. 3.5A). Furthermore, cells were labeled with Abs 
against CD44, Vcam-1 (vascular cell adhesion molecule-1, CD106) and gp38 to distinguish 
cultures of epithelial and fibroblast cell clones (Fig. 3.5A). Cells from several clones 
expressed high levels of CD44, Vcam-1 and gp38, well-established markers for fibroblasts 
(143). In contrast, other cultures of cloned cells expressed high levels of CD44, but were 
nearly devoid of Vcam-1 and gp38, indicative of epithelial cells. Their epithelial origin was 
confirmed by immunostainings for Keratin 5 and 8 (K5/8), established differentiation markers 
of TECs (Fig. 3.5B) (144). Thus, il-7 reporter cell lines of pure thymic epithelial and 
fibroblastic origin were established from Tag+ mice. IFN-γ upregulates il-7 expression in 
keratinocytes (145). In order to test il-7 gene regulation in Tag-immortalized thymic epithelial 
and fibroblast cell lines, cells were treated with recombinant murine IFN-γ (50 ng/ml). Upon 
IFN-γ stimulation, il-7 and luciferase mRNA expression increased significantly compared to 
unstimulated cells indicating similar gene regulation for the il-7 gene and the luciferase 
transgene in epithelial and fibroblastic cells, respectively (Fig. 3.5C-D). It also shows that the 
Tag+ immortalized cells still retained their capacity to regulate il-7 expression. In conclusion, 
the IL-7GCDL mouse seems to faithfully report il-7 gene activity via luciferase expression 
and offers a new and simple way to study il-7 gene regulation in isolated cells in vitro or the 
whole organism in vivo.  
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Figure 3.5: Thymic stromal cells express il-7 and luciferase in vitro. 
Cell cultures derived from the thymus of IL-7GCDLxloxP-Tag mice were cloned to obtain 
fibroblastic and epithelial cells. (A) These cultures were further analyzed for the expression of 
Tag, CD44, Vcam-1 and gp38 by flow cytometry. Relative expression of the indicated 
markers is shown for one representative of 3-4 cloned cell lines. (B) Cultured thymic 
epithelial cell clones were analyzed by immunostaining for the expression of cytokeratin 5/8 
(K5/8). As a control (ctrl), the cells were stained with the secondary Ab only. Pictures are 
representative of 2 tested clones in 2 independent experiments. (C) Thymic epithelial cells or 
(D) fibroblasts were cultured in the presence or absence of recombinant murine IFN-γ 
(50 ng/ml) for 24 h. mRNA amounts for il-7 and luciferase (luc) were determined by 
quantitative real-time PCR and normalized to β-actin or hprt and to amounts expressed by 
unstimulated cells. Graphs show representative data ± SD for 3-4 cloned cell lines. 
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3.2 Host IL-7R signaling and IL-7 therapy 
IL-7 is a potent growth and survival factor for T cells but its amount is limited in the body 
(146). Exogenous IL-7 administration is currently studied as a novel therapy to overcome 
lymphopenia or to enhance the protective function of T cells against cancer or infectious 
diseases (for details see www.clinicaltrials.gov). Albeit IL-7 therapy has been shown to 
improve the function of anti-tumor CD8+ T cells in preclinical models, tumor rejection has 
hardly been accomplished (147). Indeed, a negative feedback on endogenous il-7 production 
by splenic stromal cells has been observed after IL-7 administration (91). This suggests that 
IL-7R signaling in host cells might limit the success of IL-7-supported T cell therapy. We 
hypothesize that several cell types, especially those producing IL-7, might be sensitive to 
IL-7 treatment thereby affecting the outcome of IL-7-supported T cell therapy. First, we asked 
whether stromal cells that are main sources of IL-7 in the body can integrate signals from 
IL-7. Since our data indicated that the intestine produces high amounts of IL-7 (Fig. 3.1C) 
and (63), we assessed the expression of the IL-7Rα-chain (CD127) on colonic epithelial cells 
(CECs). We detected the expression of CD127 on CECs, yet it was very weak in comparison 
to levels observed on splenic CD8+ OT-I T cells (Fig. 3.6A). However, the expression was 
specific as validated by comparison of CECs from Rag-deficient (Rag-) to CECs from IL-7Rα-
deficient Rag- mice (IL-7R-xRag-) (Fig. 3.6A). In support of our data, functional IL-7R 
expression has also been shown in human intestinal epithelial cells (148). This indicates that 
different stromal cell types in the body, such as splenic stromal and intestinal epithelial cells, 
can sense IL-7 availability. In order to test whether IL-7 therapy affects host il-7 gene activity 
systemically, IL-7GCDL mice were treated with a mixture of recombinant murine IL-7 and 
stabilizing anti-IL-7 antibodies. These rIL-7/αIL-7 complexes improve/prolong the biological 
activity of IL-7 (149). Its use is termed “IL-7 therapy” hereafter. As shown in Figure 3.6B, BL 
signals were reduced by 25% 24 hours after IL-7 therapy. This shows that host cells respond 
to IL-7 therapy and that a single treatment with IL-7 lowers il-7 gene activity systemically. 
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Figure 3.6: IL-7 administration decreases host il-7 expression. 
(A) To detect IL-7R expression, epithelial cells were isolated from the colon of Rag- and 
IL-7R-xRag- mice (top). CD8+ T cells were isolated from spleens of Rag-OT-I+ mice (bottom). 
The levels of IL-7Rα (CD127) expression were determined by flow cytometry. Shown are 
relative cell numbers and relative fluorescence intensities for CD127 after gating on 7AAD- 
CD45-EpCam+ epithelial cells (top) and after gating on 7AAD-CD8+Vα+ OT-I T cells (bottom). 
As control, OT-I T cells were incubated with secondary antibodies only (bottom). Results are 
representative for 2 (bottom) and 3 (top) independent experiments. (B) To detect whether 
IL-7 administration alters il-7 expression, luciferase activity in IL-7GCDL mice was 
determined by in vivo BL imaging before and 24 h after i.p. injection of IL-7/α-IL-7 mix (5 µg 
IL-7 mixed with 50 µg anti-IL-7 Ab M25). BLI signals of one representative mouse before and 
24 h after IL-7 treatment are shown (left). BLI signals from mice 24 hours after IL-7 injection 
in relation to values obtained before treatment (rel. BLI) were determined (right). Shown are 
pooled data ± SEM of 2 experiments with a total of 6 mice. Statistical analysis was performed 
using Wilcoxon matched-pairs signed rank test. 
 
To test whether host cells responding to IL-7 therapy affect the outcome of ATT (of cancer) 
we used Rag- and IL-7R-xRag- mice and first analyzed the hematopoietic host cell 
population. We decided for animals on the T and B cell-deficient Rag- background since IL-7 
therapy is mostly indicated in immunocompromised, lymphopenic patients. After 10-24 days 
of IL-7 therapy, splenic cellularity increased 5-fold in Rag- mice, which was not observed in 
IL-7R-xRag- mice (Fig. 3.7A). In line with published results showing IL-7R-dependent 
development of immature B cells (150, 151), the frequency of CD19+ pro-B cells was higher 
in Rag- compared to IL-7R-xRag- mice. IL-7 therapy could raise the frequency of pro-B cells 
30-fold in an IL-7R-dependent way (Fig. 3.7B). This confirms that IL-7 therapy is highly 
biologically active (149). We also determined the frequency of other cell types in spleen that 
have previously been shown to develop independently of IL-7R signals (104). The majority of 
splenic cells belonged to the myeloid CD11b+ compartment which mainly consist of 
neutrophils, monocytes and macrophages (152). As expected, the number of CD11b+ 
myeloid cells and of Gr-1 (granulocyte-differentiation antigen-1)-expressing myeloid cells was 
similar in both untreated hosts (Fig. 3.7C-D), affirming that IL-7R signaling is not important 
for the generation of these cells. After 10-24 days of IL-7 therapy, however, myeloid cell 
B A 
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numbers increased 3,5- to 4,8-fold in spleens of Rag- mice. Based on the expression pattern 
of Gr-1 the myeloid cell subsets accumulated equally strong after IL-7 therapy. This effect 
was not observed in spleens of IL-7R-xRag- mice in which splenic cellularity remained 
unaltered (Fig. 3.7A, C-D). Since most myeloid cells do not express the IL-7R (107) the 
observed effect on those cells is presumably indirect.  
 
 
Figure 3.7: IL-7 therapy increases splenic cellularity.  
Rag- and IL-7R-xRag- mice received IL-7 therapy or PBS i.p. every 4 days for 10-24 
days. (A) Total number of splenocytes and of (B) CD19+ pro-B cells, (C) CD11b+ myeloid 
cells and (D) CD11b+Gr1+ myeloid cells were determined by flow cytometry. Graphs show 
pooled data from 2 independent experiments with a total of 7-8 mice ±SEM per group.  
 
Although conventional DCs in spleen do not express the IL-7R, IL-7R-mediated signaling 
was shown to promote DC generation at early stages of their development (104). The 
number of conventional DCs (defined as CD11c+MHC-II+) was similar in spleens of untreated 
Rag- and IL-7R-xRag- mice and increased after IL-7 therapy in Rag- mice exclusively (Fig. 
3.8A). We further assessed the composition of DC subsets with focus on CD8+ DCs, since 
this subset is known for its high capacity to cross-present Ag to T cells (153) and thus might 
be of particular value during ATT of cancer. Absolute numbers of CD8+ DCs were similar in 
spleens of PBS-treated Rag- and IL-7R-xRag- (Fig. 3.8B). Remarkably, the number of CD8- 
DCs was 3-fold higher in spleens of PBS-treated Rag hosts (Fig. 3.8C). This indicates that 
the steady-state generation/accumulation of CD8- but not CD8+ DCs in spleen is dependent 
on IL-7R-mediated signals. Splenic DC numbers increased after IL-7 therapy in Rag- mice 
exclusively (Fig. 3.8A-C). 
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Figure 3.8: Host IL-7R signaling promotes DC expansion.  
Rag- and IL-7R-xRag- mice received IL-7 therapy or PBS i.p. every 4 days for 10-24 
days. (A) Absolute numbers of CD11c+MHC-II+ cells (DCs) and its subset of (B) CD8+ and 
(C) CD8- DCs in spleen were determined. The expression levels of (D) MHC-II, (E) CD54, (F) 
CD86, (G) CD40 and (H) MHC-I were analyzed by flow cytometry on splenic CD11c+MHC-II+ 
cells (B-D) or CD11c+ cells (E-F). Data shown in (D-H) were normalized to the mean values 
obtained from PBS-treated Rag- mice. Pooled data of 2 independent experiments with a total 
of 7-8 mice ±SEM per group are shown. 
 
We further investigated the phenotype of DCs to elucidate whether host IL-7R signals affect 
the expression of molecules implicated in T cell activation. Interestingly, the expression of 
MHC-II was higher on DCs from Rag- compared to IL-7R-xRag- mice and decreased upon 
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IL-7 therapy to levels expressed by DCs from IL-7R-xRag- mice (Fig. 3.8D). The expression 
of the T cell costimulatory molecules CD54 and CD86 was similar on DCs from Rag- and 
IL-7R-xRag- mice. However, the levels of both molecules decreased after IL-7 therapy on 
DCs from Rag- animals (Fig. 3.8E-F). Yet, IL-7 therapy had no effect on DCs from IL-7R-
xRag- mice (Fig. 3.8A-F). Besides, the levels of the costimulatory molecule CD40 and MHC-I 
were not significantly regulated by IL-7R-mediated signaling in CD11c+ cells (Fig. 3.8G-H), 
indicating that IL-7 therapy impairs the expression of distinct molecules by DCs, which are 
implicated in T cell activation.  
In summary, steady state IL-7R signaling leads to increased frequencies of pro-B cells and 
CD8- DCs in spleen. Additionally, it regulates the expression of MHC-II on DCs. Strong IL-7R 
signaling induced by IL-7 therapy raises splenic cellularity, including pro-B cell, myeloid cell 
and DC numbers. Moreover, it affects the phenotype of DCs. Hence we showed that multiple 
host immune cells respond to IL-7 and could therefore affect the outcome of ATT. Especially 
DCs are important for CD8+ T cell responses. Thus, their IL-7 therapy-induced expansion 
might promote the success of ATT. However, IL-7 therapy decreased the expression of T cell 
costimulatory molecules by DCs that in turn might impair the efficacy of ATT. 
3.3 Effects of host IL-7R signaling on adoptive T cell therapy 
To determine whether host IL-7R signaling affects the success of ATT, IL-7R-competent 
and -deficient hosts were reconstituted with mature CD8+ T cells and their numbers and 
phenotype were followed. We aimed to use a T cell population with defined Ag-specificity. 
For this purpose, we performed adoptive transfer experiments with CD8+ T cells from the 
well-characterized TCR-transgenic OT-I mouse. All CD8+ OT-I T cells express a transgenic 
TCR that is specific for the SIINFEKL peptide derived from chicken-ovalbumin (154).  
3.3.1 Effects of host IL-7R signaling on adoptive T cell therapy during LIP 
The first question we addressed was whether host IL-7R signaling affects lymphopenia 
induced proliferation (LIP). LIP allows the generation of memory-like cells, which are similar 
to memory CD8+ T cells that were generated in response to foreign Ag recognition (53, 155). 
Equal numbers of MACS-purified, TCR-transgenic CD90.1 congenic CD8+ OT-I T cells 
(Fig. 3.9A) were adoptively transferred into Rag- and IL-7R-xRag- mice. 3-4 weeks after 
transfer, CD8+ OT-I T cells upregulated CD44 expression levels in Rag- and IL-7R-xRag- but 
not WT mice, which indicated their successful development into memory-like cells in the 
lymphopenic environment (Fig. 3.9B). Only low numbers of transferred T cells were 
recovered from WT mice (Fig. 3.9C). In contrast, similar numbers of OT-I T cells were 
recovered from spleens of Rag- and IL-7R-xRag- mice 3-4 weeks after T cell transfer 
(Fig. 3.9C). These data indicate that LIP occurs efficiently in IL-7R- hosts independently of 
the observed differences in DC differentiation. LIP is also dependent on intact SLO structure 
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(156). Hence, these results also prove that the SLOs in IL-7R- mice are able to support 
homeostatic proliferation including generation of memory-like CD8+ T cell.  
 
Figure 3.9: Lymphopenia-induced T cell proliferation (LIP) is independent of host IL-7R 
signaling. 
Rag-, IL-7R-xRag- and WT mice were reconstituted with 1x106 MACS-purified CD8+CD90.1+ 
OT-I T cells. 21-27 days later, (A) splenic OT-I T cells were analyzed by flow cytometry after 
gating on CD8+CD90.1+ cells (representative dot plot). (B) CD44 expression levels were 
determined on splenic OT-I T cells from all 3 recipients (Rag-, red; IL-7R-xRag-, green; WT, 
black line) and compared to CD44 isotype-matched control staining (ctrl, grey filled line; 
representative histogram). (C) Splenic OT-I T cell numbers were calculated for the different 
recipients and pooled data from 3 independent experiments with a total of 9-19 mice per 
group ±SEM are shown. 
 
Next, we asked whether the observed effects of IL-7 therapy on host cells (Fig. 3.7-3.8) 
affect LIP. Mice received IL-7 therapy or PBS i.p. one day prior and 3 days post i.v. transfer 
of 1x106 MACS-purified OT-I T cells. To test whether the transferred OT-I T cells responded 
to IL-7 therapy, IL-7Rα (CD127) expression was measured, since it is downregulated in 
response to IL-7 binding (100). As depicted in Fig. 3.10A, 5 days after transfer, the 
expression of CD127 was higher on OT-I T cells transferred into Rag- hosts than into IL-7R-
xRag- recipients, presumably due to higher amounts of IL-7 in IL-7R- hosts (91). IL-7 therapy 
decreased the expression of CD127 on T cells transferred into both hosts to a similar level. 
This indicates that T cells responded to IL-7 therapy in both hosts. IL-7 administration was 
shown to increase peripheral T cell numbers by inducing proliferation and prolonging survival 
(149, 157). To distinguish proliferation from survival, T cells were labeled with the dye CFSE 
that allows visualization of T cell division. Within 5 days after transfer, T cells divided equally 
well in both hosts as determined by the CFSE profile of splenic OT-I T cells (Fig. 3.10B-C). 
These results support our findings that LIP of CD8+ OT-I T cells is efficient in IL-7R- hosts. 
Upon IL-7 therapy, the frequency of OT-I T cells with more than 2 divisions increased 
similarly in both hosts compared to PBS-treated controls (Fig. 3.10B-C). Hence, it can be 
concluded that host IL-7R signaling does not affect IL-7-dependent CD8+ T cell expansion in 
the first 5 days of LIP. These results also suggest, that our experimental system is suitable to 
discriminate between IL-7-therapy-mediated effects on host vs. T cells. 
  
A B C 
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Figure 3.10: Host IL-7R signaling is not required for early T cell expansion after IL-7 
therapy. 
Rag- and IL-7R-xRag- mice received IL-7 therapy or PBS i.p. 24 h prior and 72 h after i.v. 
transfer of 1x106 MACS-purified CFSE-labeled OT-I T cells. 5 days after transfer, splenic 
CD8+ OT-I T cells were analyzed by flow cytometry for the intensity of (A) CD127 expression 
and (B-C) CFSE. Data shown in A were normalized to the mean values obtained from 
PBS-treated Rag- mice. (B) Representative histograms for CFSE intensities of OT-I T cells 
are shown. As controls, filled and open grey curves show undivided cells in WT hosts or 
CFSE-negative cells, respectively. (C) The number of OT-I T cell divisions was determined 
by CFSE intensity loss. Cells with more than 2 divisions are shown. Graphs show pooled 
data from 2 independent experiments with a total of 8 mice ±SEM per group.  
 
T cell expansion was further analyzed after 2 and 3 weeks of LIP and IL-7 therapy. In 
accordance with Fig. 3.7A, splenic cellularity was similar in both PBS-treated hosts 11 and 
21-25 days after T cell transfer (Fig. 3.11A, C). In the same period, IL-7 therapy increased 
splenic cell number in Rag- hosts but not in IL-7R-xRag- hosts (Fig. 3.11A, C). 11 days after 
transfer, splenic OT-I T cell numbers were elevated in IL-7R-xRag- compared to Rag- hosts 
(Fig. 3.11B). IL-7 therapy increased T cell numbers in both hosts, leading to highest T cells 
numbers in IL-7R-xRag- mice (Fig. 3.11B). While IL-7 therapy continued to induce higher T 
cell numbers in spleen 21 days after transfer, splenic T cell numbers equaled in both hosts 
(Fig 3.11D). In conclusion, IL-7 therapy induces spleen enlargement exclusively in Rag- 
hosts. In contrast, it raises splenic T cell numbers efficiently in both, Rag- and IL-7R-xRag- 
hosts.  
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Figure 3.11: Host IL-7R signaling is not required for T cell expansion after IL-7 therapy. 
Rag- and IL-7R-xRag- mice were treated i.p. with IL-7 therapy or PBS every 3-4 days starting 
one day prior to i.v. transfer of 1x106 MACS-purified OT-I T cells. 11 (A-B) and 21-25 (C-D) 
days post T cell transfer, splenic CD8+ Thy1.1+ OT-I T cells were analyzed. The number of 
(A, C) splenic cells and (B, D) splenic OT-I T cells was determined by flow cytometry. Graphs 
show pooled data from 2 independent experiments with 6-9 mice ±SEM per group. 
 
In addition, the phenotype of the transferred OT-I T cells was analyzed after 21-25 days of 
LIP. As already shown in Fig. 3.9, high CD44 expression levels were observed on most OT-I 
T cells 3 weeks after transfer into Rag- and IL-7R-xRag- hosts, indicating that they had 
developed into memory T cells (data not shown). The frequency of CD62L+ TCM, was higher 
in IL-7R-xRag- compared to Rag- animals (Fig. 3.12A). Conversely, KLRG-1, a marker for 
short-lived effector T cells (TSLEC) and TEM cells, was expressed by fewer T cells in IL-7R
-
xRag- mice (Fig. 3.12B). This suggests that TCM differentiation was facilitated in IL-7R
-xRag- 
hosts. The levels of CD127 were similar on T cells in both hosts 21-25 days after transfer 
(Fig. 3.12C), which is in contrast to data obtained 5 days after T cell transfer (Fig. 3.10A). To 
determine the level of IL-7R signaling, we measured the expression of the anti-apoptotic 
molecule Bcl-2, which is induced by IL-7R signaling (81, 157). Interestingly, the levels of 
Bcl-2 were increased in T cells reisolated from IL-7R-xRag- hosts, which is an indicator of 
higher IL-7-mediated signaling in those hosts. Furthermore, the effector function of the 
transferred T cells was assessed after short-term in vitro restimulation with the cognate 
peptide. A mildly decreased capacity to produce IFN-γ was detected in T cells reisolated 
from Rag- hosts. In summary, the differentiation towards TCM is impaired in the host IL-7R-
expressing host. This correlates with reduced levels of Bcl-2 and reduced capacity to 
produce the immunomodulatory cytokine IFN-γ.  
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When mice received IL-7 therapy concomitantly, increased frequencies of CD62L+ OT-I 
T cells but decreased rates of KLRG-1+ OT-I T cells were observed in both hosts, indicating 
that IL-7 therapy boosted TCM differentiation (Fig. 3.12A-B). IL-7 therapy also augmented 
CD127 levels on T cells in both hosts (Fig. 3.12C), which is in contrast to the effects of IL-7 
therapy observed early after application (Fig. 3.10A). Since most T cells after 5 days of LIP 
had not adopted a memory-like phenotype based on the expression of CD44 (data not 
shown), this suggests that the regulation of CD127 expression may depend on the 
differentiation state of a cell. As expected, IL-7 therapy elevated the levels of Bcl-2 in T cells 
from Rag- mice, however the levels remained lower than in T cells from IL-7-treated IL-7R-
xRag- mice (Fig. 3.12D). We also compared the capacity of OT-I T cells to produce IFN-γ 
after IL-7 therapy. Yet, OT-I T cells recovered from Rag- and IL-7R-xRag- mice produced 
IFN-γ equally well after short-term in vitro restimulation with the cognate peptide (Fig. 3.12E). 
In summary, the differentiation towards TCM was facilitated by IL-7 therapy, especially in the 
IL-7R-deficient host. This correlated with elevated levels of the anti-apoptotic molecule Bcl-2. 
However, IL-7 therapy did not raise the effector function of T cells, as judged by the capacity 
to produce IFN-γ. 
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Figure 3.12: TCM differentiation is increased after IL-7 therapy. 
Rag- and IL-7R-xRag- mice received IL-7 therapy or PBS i.p. every 4 days starting one day 
prior to i.v. transfer of 1x106 MACS-purified OT-I T cells. 21 days post T cell transfer, CD8+ 
Thy1.1+ OT-I T cells isolated from spleen were analyzed by flow cytometry for the expression 
of (A) CD62L, (B) KLRG-1, (C) CD127 and (D) Bcl-2. (E) The production of IFN-γ by OT-I 
T cells was determined after in vitro restimulation of splenocytes for 6 h with 1 mM SIINFEKL 
peptide in the presence of brefeldin A. Data shown in A-E were normalized to the mean 
values obtained from PBS-treated Rag- mice. Graphs show pooled data from 2-3 
independent experiments with a total of 7-13 mice ±SEM per group. 
 
In order to determine whether the observed effects of IL-7 therapy and host IL-7R signaling 
on adoptive T cell therapy modulate the T cell response towards Ag-expressing tumor cells, 
CD8+ OT-I T cells were transferred into both Rag- and IL-7R-xRag- hosts, which received IL-7 
therapy or PBS for 22 days. This was followed by s. c. challenge with EG7 tumor cells. We 
excluded any impact of residual IL-7 therapy on the tumor or tumor microenvironment by 
simultaneously applying the tumor cell line and IL-7 therapy in separate groups of mice that 
had not received ATT. In these Rag- and IL-7R-xRag- mice, tumor growth kinetics was 
unaffected by IL-7 therapy (Fig 3.13A). Yet, in some but not all experiments, tumors grew 
slightly slower in Rag- than in IL-7R-xRag- mice. In comparison to untreated animals, ATT 
prolonged the tumor-free period or even prevented tumor outgrowth completely. Surprisingly, 
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IL-7 therapy in addition to ATT did not alter tumor incidence in IL-7R-xRag- mice. There, 
tumor growth was prevented in 3/11 mice receiving PBS and 3/12 mice receiving IL-7 
therapy (Fig. 3.13B). In Rag- mice that received ATT however, tumor growth was prevented 
in 1/11 mice receiving PBS but in 7/12 mice receiving IL-7 therapy (Fig. 3.13C). This 
suggests that IL-7 therapy promotes the anti-tumor response of CD8+ T cells in IL-7R-
competent but not in -deficient Rag- hosts.  
 
Figure 3.13: Host IL-7R expression is required for IL-7 therapy-assisted ATT.  
(A) Mice were challenged s.c. with ova-expressing EG7 tumor cells and received IL-7 
therapy or PBS i.p. every 3-4 days starting one day before tumor challenge. Tumor growth 
was determined every 2-4 days. Graphs show representative data from 1 out of 2 
experiments with 4-5 mice/group ±SEM. (B) IL-7R-xRag- and (C) Rag- mice were 
reconstituted with 7-10x105 MACS-purified CD8+ OT-I T cells (+OT-I) and received (B, C) 
IL-7 therapy (+IL-7) or PBS every 4 days for 18 days starting one day before T cell transfer. 
22-23 days after OT-I T cell transfer, these mice and untreated controls (untr.) were 
challenged s.c. with ova-expressing EG7 tumor cells. Mice with tumors >250mm3 were 
scored as positive. Pooled data from 2 independent experiments with a total of 10-12 mice 
per group are shown. Statistical significance was calculated using the log-rank test. 
 
The limited success of IL-7 treatment on adoptive T cell therapy against cancer in 
IL-7R-deficient Rag- mice was unexpected since IL-7 therapy-assisted CD8+ OT-I T cell 
expansion occurred equally well in IL-7R-competent and -deficient animals (Fig. 3.11D). 
Although the IL-7 therapy-induced T cell numbers could not be fully sustained 4 weeks post 
tumor challenge and cessation of IL-7 treatment, OT-I T cell numbers ranged at similarly high 
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levels in spleens of tumor-bearing IL-7R-xRag- compared to Rag- mice (Fig. 3.14A). At this 
stage, the T cell phenotype was still controlled by the host, as evidenced by slightly lower 
frequencies of CD62L+ but higher rates of KLRG-1+ cells within the OT-I T cells reisolated 
from Rag- hosts (Fig. 3.14B-C). However, the phenotypic changes caused by IL-7 therapy 
were no longer present, as judged by CD62L, KLRG-1 and CD127 expression pattern 
(Fig. 3.14B-D).  
 
Figure 3.14: Host IL-7R signaling is not required for maintaining T cell numbers and 
effector functions 4 weeks post tumor challenge. 
4-10x105 MACS-purified OT-I T cells were transferred into Rag- and IL-7R-xRag- hosts. Mice 
received IL-7 therapy or PBS i.p. every 4 days for 19 days starting one day before T cell 
transfer. 3 weeks after T cell transfer, mice were challenged s.c. with 1x106 EG7 tumor cells. 
Splenic cells were analyzed from mice with large tumors 28-35 days after EG7 challenge. 
Frequencies of (A) T cells and (B) relative frequencies of CD62L+ and (C) KLRG-1+ cells as 
well as the relative expression of (D) CD127 within the OT-I T cell pool are shown. The 
production of (E) IFN-γ and (F) TNF-α by OT-I T cells was determined after in vitro 
restimulation of splenocytes for 6 h with 1 µM SIINFEKL peptide and brefeldin A. Data shown 
in B-F were normalized to the mean values obtained from PBS-treated Rag- mice. Shown are 
pooled data from 2 independent experiments with a total of 6-9 mice ±SEM per group. 
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To determine whether the large remaining population of tumor-specific T cells lost effector 
function and therefore allowed tumor outgrowth, their ability to produce IFN-γ and TNF-α was 
assessed after short in vitro restimulation with the cognate peptide. More than 50% of the 
OT-I T cells reisolated from spleen were still able to produce these cytokines indicating that 
they were not completely exhausted (raw data not shown). More importantly, these 
frequencies were similar in all tested groups (Fig. 3.14E-F). In conclusion, although T cell 
proliferation and effector function was similar in both hosts, IL-7 therapy exclusively 
promoted responses of tumor-specific T cells in the IL-7-responsive Rag- hosts. This 
indicates that host IL-7R signaling is required for the success of IL-7 therapy-assisted ATT. 
3.3.2 Effects of host IL-7R signaling on adoptive T cell therapy combined with 
immunization 
As observed above, adoptive T cell therapy alone can be insufficient in mediating anti-tumor 
responses. In this condition, acute TCR stimulation can help to boost anti-cancer responses 
of therapeutic T cells (158). Hence it was recently suggested to include vaccinations into 
future clinical trials (135). In order to determine the effect of IL-7 therapy on T cell 
proliferation and function upon acute TCR stimulation, the experiments were extended by 
peptide vaccinations.  
CD8+ OT-I T cells were transferred into Rag- and IL-7R-xRag- hosts, which were immunized 
with 50 µg SIINFEKL peptide one day later. In addition the animals received IL-7 therapy or 
PBS every 4 days starting one day prior to T cell transfer. 3 weeks after T cell transfer, we 
did not observe any significant difference in splenic cellularity comparing both immunized 
hosts (Fig. 3.15A). Since peptide vaccination induces effector T cells and TSLEC / TEM that 
have the capacity to migrate from SLOs to the periphery (36), T cells circulating through the 
blood were also analyzed. Numbers of OT-I T cell were slightly higher in spleens and blood 
of immunized Rag- compared to IL-7R-xRag- hosts (Fig. 3.15B-C). Surprisingly, the 
combination of immunization and IL-7 therapy led to very high T cell frequencies in spleen 
and blood of Rag- compared to IL-7R-xRag- mice and animals, that did not receive IL-7 
therapy (Fig. 3.15B-C). This indicates that IL-7R signaling in host cells is needed for strong 
T cell expansion upon TCR stimulation. In addition to T cell frequencies, the phenotype of the 
transferred OT-I T cells was analyzed. The frequency of CD62L+ TCM cells within the OT-I 
T cell pool was unchanged in spleen or blood of immunized Rag- and IL-7R-xRag- hosts and 
increased after IL-7 therapy to similar levels in both hosts (Fig. 3.15D-E). The expression of 
CD127 on T cells from spleen or blood was mildly elevated in Rag- compared to IL-7R-xRag- 
hosts (Fig. 3.15F-G). IL-7 therapy strongly increased CD127 levels on T cells exclusively in 
IL-7R-competent Rag- mice (Fig. 3.15F-G). These results demonstrate that IL-7 therapy-
induced T cell expansion and expression of the memory (precursor)-associated molecule 
CD127 (87) are dependent on an IL-7 responsive host environment.  
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Figure 3.15: Enhanced T cell proliferation in response to peptide vaccination and IL-7 
therapy depends on host IL-7R signaling. 
Rag- and IL-7R-xRag- mice received 1x106 MACS-purified OT-I T cells i.v. and were 
immunized with 50 µg SIINFEKL peptide one day after T cell transfer. Additionally, mice 
received IL-7 therapy (imm+IL-7) or PBS (imm) i.p. every 4 days starting one day prior to 
T cell transfer. 3 weeks later, (A) the number of splenic cells and number of CD8+ Thy.1.1+ 
OT-I T cells in (B) spleen and (C) blood was determined by flow cytometry. The frequency of 
(D-E) CD62L+ cells within the OT-I T cell pool and the expression level of (F-G) CD127 on 
OT-I T cells from spleen and blood are shown, respectively. Data shown in D-G were 
normalized to the mean values obtained from PBS-treated (imm) Rag- mice. Shown are 
pooled data from 2-5 independent experiments with a total of 9-26 mice ±SEM per group. 
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The data presented in Fig. 3.15B-G also show that in our model, T cells have a similar 
phenotype and distribution in spleen and blood, suggesting that analysis of circulating T cells 
from peripheral blood is representative for splenic T cells. The TSLEC / TEM associated 
molecule KLRG-1 was expressed by more T cells in blood of immunized IL-7R-xRag- mice 
(Fig. 3.16A). IL-7 therapy decreased the frequency of KLRG-1 expressing T cells in both 
hosts leading to almost undetectable KLRG-1 expression on T cells in IL-7R-competent 
hosts (Fig. 3.16A). Together with data showing that IL-7 therapy increased the frequency of 
CD62L+ T cells (Fig. 3.15D-E), the results indicate more pronounced TCM generation in the 
presence of IL-7 therapy. However, the so far observed inverse relation of CD62L and 
KLRG-1 expression on transferred T cells undergoing LIP (Fig. 3.12A-B) was not observed 
after vaccination. In vaccinated animals, the frequency of CD62L+ T cells was similar, but the 
rate of KLRG-1+ T cells was elevated in IL-7R-xRag- mice (Fig. 3.15E vs. 3.16A). Hence, it 
was difficult to infer the differentiation to TCM (CD62L
+KLRG-1low) or TEM/SLEC (CD62L
-
KLRG-1+) from this analysis. In order to conclude whether host IL-7R expression alters the 
memory differentiation after peptide vaccination, we included the analysis of T-bet and 
Eomes. The balanced expression of these transcription factors determines effector vs. long-
lived TM cell differentiation (97, 159–161). T-bet was expressed at similar levels by T cells in 
both hosts and decreased after IL-7 therapy (Fig. 3.16B). The expression pattern of T-bet 
correlated negatively with CD62L (Fig. 3.15E, 3.16B). Eomes was expressed at similar levels 
by T cells in both hosts (Fig. 3.16C). After IL-7 therapy, T cells in Rag- hosts retained these 
levels, whereas T cells transferred into IL-7R-xRag- hosts increased Eomes expression (Fig. 
3.16B). While T-bet is expressed by effector T cells but declines during memory formation, 
Eomes expression increases (162). Thus, we suggest that IL-7-responsive host cells affected 
the generation of TSLEC vs. TM cells after vaccination and IL-7 therapy. Additionally, we 
determined the expression levels of the anti-apoptotic and IL-7-inducible TM-precursor and 
TM-associated molecule Bcl-2 (163). T cells isolated from immunized IL-7R-competent 
and -deficient hosts expressed similar levels of Bcl-2 (Fig. 3.16D). After IL-7 therapy, Bcl-2 
expression remained stable in T cells in Rag- hosts, but increased in T cells transferred into 
IL-7R-xRag- mice. This expression pattern correlates with Eomes and indicates high survival 
capacities of the few T cells in IL-7-treated immunized IL-7R-xRag- hosts. Besides this 
survival-promoting factor, we also assessed the proliferative state of the transferred T cells. 
T cells in Rag- mice exhibited a lower basic proliferation rate than T cells in IL-7R-xRag- mice 
as assessed by the marker Ki-67 (Fig. 3.16E). However IL-7 therapy raised those rates to 
levels observed in IL-7R-deficient hosts. These data indicate that host IL-7R signaling does 
not improve the survival or proliferation of the OT-I T cells 3 weeks after transfer, suggesting 
that IL-7-responsive host cells facilitate IL-7 therapy-induced T cell expansion early after 
vaccination.  
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Figure 3.16: Eomes and Bcl-2 expression by T cells in response to peptide vaccination 
and IL-7 therapy is regulated by host IL-7R signaling. 
Rag- and IL-7R-xRag- mice received 1x106 MACS-purified OT-I T cells i.v. and were 
immunized with 50 µg SIINFEKL peptide one day after T cell transfer. Additionally, mice 
received IL-7 therapy (imm+IL-7) or PBS (imm) i.p. every 4 days starting one day prior to 
T cell transfer. 3 weeks later, peripheral blood CD8+ OT-I T cells were analyzed for (A) the 
frequency of KLRG-1+ and (E) Ki-67+ cells and for the MFI of (B) T-bet, (C) Eomes and (D) 
Bcl-2 by flow cytometry. Data shown in A-E were normalized to the mean values obtained 
from PBS-treated (imm) Rag- mice. Shown are pooled data from 3 independent experiments 
with a total of 16-18 mice ±SEM per group. 
 
We continued to assess phenotypic markers implicated in T cell responsiveness. The 
intensity of TCR and CD8 co-receptor expression sets the Ag responsiveness of T cells (164, 
165). As the TCR is expressed on the cell surface in a complex with CD3, which is needed 
for TCR signal transduction, we determined CD3ε surface expression to determine TCR 
expression (166). 3 weeks after transfer, CD3ε levels did not differ on T cells reisolated from 
immunized IL-7R-xRag- and Rag- hosts (Fig. 3.17A). However, CD3ε levels increased after 
additional IL-7 therapy exclusively on T cells transferred into IL-7R-xRag- mice. In line with 
the expression pattern of CD3, CD8 levels were similar on T cells from immunized IL-7R-
xRag- and Rag- mice and increased after IL-7 therapy in IL-7R-xRag- mice (Fig. 3.17B). In 
contrast, CD8 levels decreased on T cells in Rag- mice after IL-7 therapy. Together, this 
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indicates that IL-7 therapy decreased TCR-mediated T cell responsiveness in immunized 
Rag- mice while increasing it in IL-7R-xRag- mice. To determine whether host IL-7R signaling 
affects TCR-mediated signaling, we measured the levels of CD5, which correlates with the 
intensity of homeostatic TCR engagement (167). The expression of CD5 was lower on 
T cells from immunized IL-7R-xRag- compared to Rag- mice (Fig. 3.17C). When immunization 
was combined with IL-7 therapy, the expression of CD5 equaled in both hosts. This indicates 
that Ag-experienced OT-I T cells have less intense contact to self-peptide MHC-complexes in 
the IL-7R- hosts. Yet, IL-7 therapy-induced upregulation of TCR and coreceptor expression 
may have restored the defect. Tonic TCR engagement is important for maintaining 
responsiveness to foreign Ag (105). Moreover T cell responses are impaired by PD-1 (168, 
169). Interestingly PD-1 was expressed at similar levels on OT-I T cells in IL-7R-xRag- and 
Rag- mice (Fig. 3.17D). IL-7 therapy selectively reduced PD-1 levels on T cells in Rag- mice. 
However, the low PD-1 level after IL-7 therapy did not substantially improve effector function 
of those OT-I T cells, which was assayed after short-term in vitro restimulation of PBMCs 
with the peptide SIINFEKL (Fig. 3.17E-G). TNF-α was produced by about 40% of the OT-I T 
cells in both hosts (data not shown and Fig. 3.17F). The percentage of TNF-α producers was 
slightly enhanced after IL-7 therapy, irrespective of host IL-7R signaling. Approximately 50% 
of the T cells were able to produce IFN-γ (data not shown). The percentage of IFN-γ-
producing T cells was slightly decreased in immunized IL-7R-xRag- (Fig. 3.17E). Yet this 
reduction was recovered by IL-7 therapy. Furthermore, the T cell’s ability to release cytotoxic 
substances by degranulation was estimated by measurement of CD107a on the T cell’s 
surface. 60-70% of the T cells were CD107a+ (data not shown). We observed a very mild 
decrease of this frequency in IL-7R-deficient hosts (Fig. 3.17G). IL-7 therapy did not alter 
these frequencies, indicating that the majority of T cells exhibited cytotoxic function 
irrespective of IL-7 therapy and host IL-7R signaling.  
In conclusion, T cell effector functions as determined by the production of the cytokines IFN-γ 
and TNF-α and the capacity to release cytotoxic substances from vesicles were not majorly 
affected by host IL-7R signaling. However, since IL-7 therapy induced a more than 10-fold 
increase in the number of T cells selectively in immunized Rag- mice (Fig. 3.15B-C), we 
conclude that the absolute number of T cells with immediate effector function is highest in 
IL-7R competent hosts. Moreover, IL-7 therapy and host IL-7R signaling were able to 
modulate Ag-driven memory T cell differentiation in immunized IL-7R-xRag- and Rag- mice. 
IL-7 therapy increased the number of TCM largely independent of host IL-7R expression, as 
assessed by the expression of CD62L, KLRG-1 and T-bet. 
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Figure 3.17: T cell effector functions in response to peptide vaccination and IL-7 
therapy are independent of host IL-7R signaling. 
Rag- and IL-7R-xRag- mice received 1x106 MACS-purified OT-I T cells i.v. and were 
immunized with 50 µg SIINFEKL peptide one day after T cell transfer. Additionally, mice 
received IL-7 therapy (imm+IL-7) or PBS (imm) i.p. every 4 days starting one day prior to T 
cell transfer. 3 weeks later, OT-I T cells from peripheral blood were analyzed for the relative 
expression of (A) CD3, (B) CD8, (C) CD5 and (D) PD-1 by flow cytometry. The production of 
(E) IFN-γ, (F) TNF-α by OT-I T cells and surface levels of (G) CD107a on OT-I T cells were 
determined after in vitro restimulation of PBMCs cocultured with splenocytes from Rag- mice 
for 6 h in the presence of 1 µM SIINFEKL peptide, brefeldin A and monensin. Data shown in 
A-G were normalized to the mean values obtained from PBS-treated (imm) Rag- mice. 
Shown are pooled data from (A) 2 independent experiments with a total of 12-13 mice and 
(B-G) 3 independent experiments with a total of 15-18 mice ±SEM per group. 
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Additionally, molecules involved in the survival of T cells (IL-7R and Bcl-2) were modulated. 
Surprisingly, IL-7R expression by host cells is required to induce high IL-7R levels on T cells 
upon IL-7 therapy. Conversely, increased expression of Bcl-2 and Eomes in OT-I T cells was 
only observed in IL-7R-deficient hosts after IL-7 therapy. These results suggest that the 
IL-7R+ host environment together with IL-7 therapy change the memory differentiation and 
the size of the memory pool.  
In a first attempt to identify those host cells involved in the regulation of T cell responses by 
IL-7, the contribution of the hematopoietic vs. non-hematopoietic host cells was analyzed. 
Mice were lethally irradiated to replace their hematopoietic system by reconstitution with 
donor BM cells. As a result, IL-7R expression was restricted either to hematopoietic cells 
(BM transfer from Rag- into irradiated IL-7R-xRag- hosts) or non-hematopoietic cells (BM 
transfer from IL-7R-xRag- into irradiated Rag- hosts). At least 6 weeks post hematopoietic cell 
reconstitution, MACS-purified OT-I T cells were transferred into BM-chimeric Rag- and IL-7R-
xRag- animals. One day later, mice were immunized i.v. with SIINFEKL peptide. In addition, 
they received IL-7 therapy every 4 days starting one day prior to T cell transfer. 3 weeks after 
transfer, the degree of BM engraftment and the number of CD11b+ myeloid cells, DCs and 
OT-I T cells were analyzed in spleen. By use of CD45.1 and CD45.2 congenic mice, we were 
able to discriminate hematopoietic cells from the donor vs. recipient. The pattern of CD45.1 
vs. CD45.2 expression by CD11b+ cells showed that the rate of BM engraftment ranged at 
97%, demonstrating that the hematopoietic system was replaced efficiently (Fig. 3.18A). We 
analyzed the splenic cell composition for CD11b+ myeloid cells and DCs, since both cell 
types regulate T cell responses and their numbers were altered after IL-7 therapy in the 
absence of ATT (Fig. 3.7C and 3.8A). Splenic CD11b+ myeloid cell and CD11c+MHC-II+ DC 
numbers were lower in spleens of IL-7R- BM-reconstituted animals (BM transfer from IL-7R-
xRag- into IL-7R-xRag- recipients; IL-7R-xRag-→IL-7R-xRag-) compared to all other chimeras 
(Fig. 3.18B-C). These results show that IL-7R expression by either hematopoietic or stromal 
cells was sufficient to reach myeloid cell and DC numbers observed in IL-7R-competent 
mice. OT-I T cell numbers were 15x higher in IL-7R-competent BM-reconstituted mice (Rag-
→Rag-) than in IL-7R- hosts (IL-7R-xRag-→IL-7R-xRag-) (Fig. 3.18D). This finding is also in 
line with data obtained in non-chimeric mice (Fig. 3.15B). When IL-7R signaling was 
restricted to non-hematopoietic cells (IL-7R-xRag-→Rag-) T cell numbers were 14x higher 
compared to the IL-7R-deficient mice. However, when IL-7R signaling was restricted to 
hematopoietic cells (Rag-→IL-7R-xRag-), T cell numbers were only 5x higher compared to 
the IL-7R-deficient animals. This indicates that the main mediators of IL-7 therapy-induced 
T cell expansion are non-hematopoietic cells. Yet, there is also a small but significant 
influence of IL-7R-expressing hematopoietic cells.  
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Figure 3.18: IL-7R signaling in non-hematopoietic cells is sufficient for high T cell 
expansion in response to peptide vaccination and IL-7 therapy. 
Lethally irradiated CD45.1+ Rag- and CD45.2+ IL-7R-xRag- mice were reconstituted with the 
indicated bone marrow (BM) cells (BM donor → recipient). At least 6 weeks later, 1x106 WT 
or luciferase-tg MACS-purified CD8+ OT-I T cells were transferred into these BM-chimeras. 
One day later, mice were immunized i.v. with 50 µg SIINFEKL peptide. IL-7 therapy was 
applied i.p. every 4 days starting one day prior to T cell transfer. (A-D) The BM-chimeric mice 
were analyzed 3 weeks after T cell transfer. (A) The degree of BM engraftment was 
evaluated by determining the frequency of splenic CD11b+ cells expressing donor-specific 
CD45.1 or CD45.2 by flow cytometry. The numbers of (B) CD11b+ cells, (C) CD11c+MHC-II+ 
DCs and (D) CD8+ OT-I T cells in spleen were determined. (E) To detect T cell numbers 
systemically, hosts were treated as described above and 100 µg colenterazine was injected 
i.v. 6 days after transfer of luciferase+ T cell and total body BL imaging was performed. 
Shown are pooled data ±SEM of (A-D) 3 or (E) 2 independent experiments with a total of (A-
D) 10-17 or (E) 5-10 mice/group. 
 
Furthermore, we wanted to know whether T cell numbers in spleen reflect T cell expansion 
systemically or whether lymphocytes migrated differently. Therefore, luciferase+ OT-I T cells 
were transferred into BM-chimeric mice and treated as described above. BL intensities 
reflecting T cell abundance in the entire body were acquired by in vivo imaging 6 days after 
T cell transfer (Fig. 3.18E). Indeed, splenic T cell numbers correlated with systemic BL 
intensities from luciferase+ OT-I T cells. These data further underline that non-hematopoietic 
IL-7-responsive host cells predominantly regulate T cell expansion in response to peptide 
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vaccination and IL-7 therapy. These results also show that this process is set in the first 
week after immunization. 
Next, the phenotypic changes of the OT-I T cells in spleen were analyzed. Surprisingly, the 
frequency of CD62L+ T cells was strongly impaired when IL-7R signaling was restricted to 
the hematopoietic compartment only (Fig. 3.19A). This reveals an unexpected interactive role 
of IL-7-expressing host cells on CD62L regulation by T cells. The CD62Llow phenotype 
correlated with highest frequencies of KLRG-1+ OT-I T cell in this group, indicating that 
memory differentiation and not only CD62L regulation was affected (Fig. 3.19B). 
Furthermore, the expression of CD127 on OT-I T cells was 2x higher in IL-7R-competent 
compared to IL-7R-deficient BM-chimeric hosts (Fig. 3.19C). This observation is in line with 
previous results in non-chimeric animals (Fig. 3.15F). When IL-7R expression was restricted 
to non-hematopoietic host cells (IL-7R-xRag-→Rag-), CD127 expression reached similarly 
high levels as in IL-7R-competent hosts, indicating that IL-7R-expression by non-
hematopoietic cells was sufficient to induce the observed regulation of CD127 on OT-I 
T cells. Yet, hematopoietic cell-restricted IL-7R expression (Rag-→IL-7R-xRag-) also 
increased CD127 expression on T cells compared to values observed in IL-7R- mice, but did 
not reach levels observed in IL-7R-competent hosts (Fig. 3.19C). Since IL-7R signaling can 
directly promote Bcl-2 expression (170), its abundance was analyzed next. The expression of 
anti-apoptotic Bcl-2 by OT-I T cells was lower in hosts, which contained IL-7R-expressing 
hematopoietic or non-hematopoietic cells compared to IL-7R- hosts (Fig. 3.19D). 
Interestingly, Bcl-2 expression correlated inversely with CD127 expression on T cells, as 
already shown (Fig. 3.16D). This suggests that IL-7R-signaling in T cells may not be 
responsible for the observed Bcl-2 regulation. Since Bcl-2 can also be induced by other 
cytokines binding to receptors of the γc-chain family (81, 171), we determined the expression 
of the γc-chain. Indeed we observed a similar pattern of γc-chain (CD132) expression as 
observed for Bcl-2 (Fig. 3.19E). Hence, we suggest that Bcl-2 might be regulated by other 
γc-chain-cytokines than IL-7. Since TM homeostasis is regulated by IL-7 and IL-15 (69), we 
speculate that γc-chain-dependent IL-15R-signaling might regulate the Bcl-2 levels of the 
OT-I T cells. Similar to the regulation of Bcl-2, Eomes expression by OT-I T cells was lower 
in hosts, which contain IL-7R-expressing hematopoietic or non-hematopoietic cells compared 
to IL-7R- animals (Fig. 3.19F). Furthermore, the levels of CD8 and PD-1 were largely 
dependent on IL-7R expression by non-hematopoietic hosts cells, although hematopoietic 
cell-expressed IL-7R could also partially downmodulate their expression (Fig. 3.19G-H). 
These data indicate that non-hematopoietic host cells are the main regulators of OT-I T cell 
expansion and differentiation after vaccination and IL-7 therapy. 
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Figure 3.19: IL-7R signaling in non-hematopoietic host cells regulates the memory 
differentiation of T cell in response to peptide vaccination and IL-7 therapy. 
Lethally irradiated Rag- and IL-7R-xRag- mice were reconstituted with the indicated bone 
marrow (BM) cells (BM donor → recipient). At least 6 weeks later, 1x106 WT or luciferase-tg 
OT-I T cells were transferred into these BM-chimeras. One day later, mice were immunized 
i.v. with 50 µg SIINFEKL peptide. IL-7 therapy was applied i.p. every 4 days starting one day 
prior to T cell transfer. 3 weeks after T cell transfer, the phenotype of the CD8+ OT-I T cells 
was analyzed in spleen. The frequency of (A) CD62L+ and (B) KLRG-1+ cells and the 
expression of (C) CD127, (D) Bcl-2, (E) CD132, (F) Eomes, (G) CD8 and (H) PD-1 were 
determined by flow cytometry. Data shown in A-H were normalized to mean values obtained 
from Rag-→Rag- mice. Shown are pooled data ±SEM of (A-D, F-H) 3 or (E) 2 independent 
experiments with a total of (A-D, F-H) 10-17 or (E) 4-10 mice/group. 
 
Next we aimed to determine whether the striking differences in OT-I T cell expansion and 
phenotype after peptide vaccination and IL-7 therapy in IL-7R signaling-competent 
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vs. -deficient mice affected the response towards tumor cells. Hence, CD8+ OT-I T cells were 
transferred into both (Rag- and IL-7R-xRag-) hosts and treated as described above. 22 days 
after transfer, these mice and untreated control groups were challenged s.c. with EG7 tumor 
cells and tumor outgrowth was monitored. ATT delayed/inhibited tumor outgrowth in 
comparison to untreated controls (Fig. 3.20A-B). IL-7 therapy did not alter tumor growth in 
immunized T cell transferred IL-7R-xRag- mice, where tumor growth was prevented in 1/12 
and 2/12 mice receiving IL-7 therapy or PBS, respectively (Fig. 3.20A). In contrast, in 
immunized T cell transferred Rag- mice, tumor growth was prevented in 6/12 mice receiving 
PBS, but only in 2/12 mice receiving IL-7 therapy (Fig. 3.20B).  
 
 
Figure 3.20: IL-7 therapy impairs T cell-dependent tumor rejection in peptide 
vaccinated Rag- mice. 
1x106 MACS-purified CD8+ OT-I T cells were transferred into (A) IL-7R-xRag- and (B) Rag- 
mice. Hosts were immunized with 50 µg SIINFEKL peptide one day after T cell transfer. Mice 
received IL-7 therapy (+IL-7+imm) or PBS (+imm) for 19 days every 3-4 days starting one 
day prior to T cell transfer. Mice were challenged s.c. with 1x106 EG7 tumor cells 22 days 
after T cell transfer. Mice with tumors larger than 250 mm3 were scored as tumor positive. 
Shown are pooled data from 2 independent experiments with a total of 12-13 T cell-
reconstituted mice. Primary tumor growth was analyzed in untreated (untr.) IL-7R-xRag- and 
Rag- mice (n=3). Statistical significance was calculated using the log-rank test. 
 
Unexpectedly, IL-7 therapy impaired the anti-tumor response in immunized IL-7R-competent 
mice, reducing the protective effect of T cell therapy from 50% to only 17%. When mice with 
large tumors were analyzed 4 weeks after tumor challenge, OT-I T cells were still most 
abundant in previously IL-7-treated, immunized Rag- mice (Fig. 3.21A). The frequency of 
CD62L+KLRG-1- TCM and the level of CD127 expression were still higher in IL-7-treated 
compared to only immunized Rag- mice (Fig. 3.21B-D). The observed phenotype may 
suggest that T cells were not able to adopt a secondary effector phenotype in previously 
IL-7-treated, immunized Rag- hosts. This would explain the impaired success of ATT in Rag- 
mice after immunization and IL-7 therapy. 
A B 
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Figure 3.21: IL-7 therapy-induced T cell expanison persists 4 weeks post tumor 
challenge. 
1x106 MACS-purified OT-I T cells were transferred into Rag- and IL-7R-xRag- hosts. Mice 
were immunized with 50 µg SIINFEKL peptide i.v. one day after T cell transfer. Additionally, 
mice received IL-7 therapy or PBS i.p. every 4 days for 19 days starting one day prior to 
T cell transfer. 3 weeks later, mice were challenged s.c. with 1x106 EG7 tumor cells. Splenic 
cells of tumor-bearing mice were analyzed 28-37 days after tumor cell injection.  
Shown are (A) absolute numbers of CD8+ OT-I T cells and frequencies of (B) CD62L+, (C) 
KLRG-1+ cells within the CD8+ OT-I T cell pool and the relative expression of (D) CD127, (E) 
PD-1 and (F) CD5 by these OT-I T cells as determined by flow cytometry. The (G) production 
of IFN-γ and (H) capacity to release cytotoxic granules (as assessed by the surrogate marker 
CD107a) was determined in OT-I T cells after in vitro restimulation of splenocytes for 6 h with 
1 µM SIINFEKL peptide in the presence of brefeldin A and monensin. Data shown in B-H 
were normalized to the mean values obtained from PBS-treated (imm) Rag- mice. Shown are 
pooled data from two 2 independent experiments with a total of 6-11 mice ±SEM per group. 
 
Results 
 53 
Moreover, the level of PD-1 equalized and CD5 expression even increased in previously 
IL-7-treated compared to only immunized Rag- hosts (Fig. 3.21E-F). Since CD5 acts as 
negative regulator of TCR signaling, these results indicate that IL-7 therapy reduced TCR 
responsiveness in Rag- hosts. This could also help to explain why IL-7 therapy impaired anti-
tumor responses of OT-I T cells in immunized Rag- hosts. However, after short-term in vitro 
restimulation with the cognate peptide SIINFEKL, more than 80% of OT-I T cells from Rag- 
mice were able to produce IFN-γ and degranulate (based on the frequency of CD107a+ cells) 
(Fig. 3.21G-H). Yet, it is unclear whether those cells efficiently reached the tumor, since they 
did not readopt an effector phenotype.  
In conclusion, the detrimental effect of IL-7 therapy in immunized mice is in stark contrast to 
the situation in unimmunized hosts, where T cells underwent LIP and were activated by very 
weak TCR stimuli through self-peptides (Fig. 3.13C). Here, tumor growth was prevented by 
IL-7 therapy in 58% of the IL-7R-competent hosts but only in 10% of the group receiving 
T cells only. These data suggest that IL-7 therapy can act like a “double-edged sword” either 
promoting or impairing the anti-tumor function of adoptively transferred T cells in an 
IL-7-responsive lymphopenic environment. More importantly, the data presented in 
Figure 3.10-21 also strongly suggest that IL-7 influences host cells that critically modulate the 
numbers and differentiation of adoptively transferred CD8+ OT-I T cells in lymphopenic 
conditions. 
In summary, the data obtained for this thesis show that next to direct effects of IL-7 therapy 
on adoptively transferred T cells, IL-7-responsive non-hematopoietic host cells mainly 
regulate the expansion and the memory differentiation of the therapeutic CD8+ OT-I T cells 
after peptide vaccination. IL-7-responsive host cells are needed for successful ATT against 
cancer after peptide immunization. However, the therapeutic success of peptide 
immunization and ATT is impaired by concomitant IL-7 therapy, despite highly efficient T cell 
expansion. Yet, in the absence of peptide vaccination, IL-7 therapy promotes the success of 
ATT against cancer exclusively in IL-7-responsive hosts. In conclusion, the IL-7-responsive 
host environment and the availability of Ag crucially affect the success of IL-7-assisted ATT 
against cancer. We show that IL-7 therapy affects DCs, myeloid and il-7-expressing stromal 
cells. Since non-hematopoietic host cells mainly regulate the expansion and the memory 
differentiation of the therapeutic CD8+ OT-I T cells after peptide vaccination, we suggest that 
il-7-expressing stromal cells modulate the success of ATT.  
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4 Discussion 
IL-7 is an essential cytokine for development and maintenance of lymphocytes (60). IL-7 
levels must be balanced tightly, on the one hand, to transmit sufficient survival signals to the 
T cell pool in order to eliminate pathogens and malignant cells and, on the other hand, to limit 
unwanted T cell activation and subsequent tissue damage. Despite its non-redundant role in 
T cell homeostasis, only a limited set of data describes the sites of IL-7 production, how IL-7 
expression is regulated and which other host cells are affected by IL-7 signaling. Most 
importantly, it remained completely unknown whether the success of IL-7-assisted adoptive 
T cell therapy against cancer is dependent on IL-7-mediated signals in host cells. 
4.1 The IL-7GCDL mouse - powerful tool to understand the regulation of il-7 gene 
expression and to manipulate il-7-expressing cells 
In order to determine which cells produce IL-7, immunohistochemistry for IL-7 in various 
organs, gene expression analysis of purified cell subsets or generation of IL-7 reporters is 
required. Since il-7 is only expressed at a low level and high-quality antibodies are not 
available for murine IL-7, immunohistochemical identification of IL-7 producing cells is not 
reliable (64). From experiments using BM-chimeric IL-7- mice, it was deducted that most IL-7-
producing cells belong to the non-hematopoietic compartment (70). The purification of non-
hematopoietic cells from tissues is a tedious, time-consuming process involving enzymatic 
digestion steps. Thus this method is accompanied by loss of sensitive cell subsets, and may 
alter gene expression profiles in the remaining cells. Therefore, it is not the preferred way to 
analyze IL-7 production. To overcome these obstacles, the IL-7GCDL reporter mouse was 
generated, in which expression of eGFP, DNA recombinase Cre, DTR and luciferase are 
controlled by the IL-7 promoter. Although eGFP mRNA expression was detectable, the 
fluorescent eGFP reporter protein could not be visualized by flow cytometry or 
immunostaining (63). We hypothesize that eGFP expression does not cross the detection 
limit due to low il-7 promoter activity. In fact, low sensitivity of fluorescing BAC-transgenic 
IL-7 reporter mice was also reported by others, where only cells expressing il-7 at high levels 
were fluorescing strong enough to allow direct or anti-fluorophore-antibody-mediated 
detection (64, 66). In contrast to eGFP, the activity of the reporter protein luciferase was well 
detectable by BL imaging in vivo. Since a single luciferase molecule can catalyze many 
reactions leading to light emission, it amplifies the reporter signal and hence leads to high 
reporter sensitivity. However, BL imaging has some caveats. The availability of cofactors 
such as Magnesium ions, oxygen and adenosintriphosphate can affect the reporter accuracy 
in vivo (172). Besides, the imaging procedure needs to be standardized precisely, since 
substrate distribution and metabolism restrict the time window when luciferase-catalyzed light 
emission is stable. In addition, the light signal cannot penetrate all tissues and gets 
quenched by hemoglobin (173). This means that the same organs from different mice can be 
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compared well. Yet, direct comparison of e.g. the dark-red spleen and light lymph node is 
inaccurate. Despite these limitations, luciferase activity proved to be a reliable reporter for il-7 
expression in organs, as we showed that it closely mimicked endogenous il-7 gene 
expression (63). Two independently generated mouse lines were analyzed and compared. 
Both lines showed a similar pattern of reporter activity comparing different organs, but one 
mouse line had overall stronger BL activity, most likely due to higher copy number of the 
transgenic reporter (Fig. 3.1). With help of the il-7 promoter-driven luciferase activity of the 
IL-7GCDL mouse, we identified various distinct tissues that contain il-7 expressing cells. We 
detected high expression of il-7 in the thymus and thereby confirmed data obtained by use of 
other IL-7 reporter mice and RNA in-situ hybridization (64–66, 142, 174). Moreover, we 
showed that due to its size, the intestine is a large source of IL-7 in the body. Additionally, we 
also affirmed il-7 expression from LNs and skin, and detected il-7 expressing cells in lung, 
which has hardly been described as source of IL-7 (Fig. 3.4) (63, 65, 174, 175). Next to the 
very high sensitivity of BL imaging, its major advantage lays in the fact that BL intensities 
reflect the expression from a region of interest such as the lung, which contains rather 
immobile il-7 producing stromal cells. When, for instance during an infection, leukocytes 
infiltrate the organ, these infiltrates can lead to falsely low relative il-7 RNA levels, since they 
lead to an increase of the RNA amount per organ. However, infiltrating cells do not interfere 
with the level of BL detected from the whole organ. This example emphasizes the benefits of 
the luciferase reporter, especially for analyzing the regulation of stromal cell-derived 
molecules like IL-7. Moreover, the mildly invasive in vivo imaging procedure (as substrate 
injection, short anesthesia) of the luciferase reporter mice allows observing il-7 gene 
regulation during the course of an experiment, such as drug treatment or an immune 
response against an infection and will thus facilitate studies on organ-specific regulation of 
il-7 gene expression.  
Moreover, il-7 promoter-controlled expression of the DNA-recombinase Cre allowed tracking 
of il-7 producers on the single cell level. We crossed the IL-7GCDL mouse to the loxP-Tag 
mouse (138) to label and amplify rare il-7 producing cells. Hence, with help of the 
IL-7GCDLxloxPTag mouse, identification and long-term culture of the rare il-7 producing cells 
was facilitated. We established Tag+ cell cultures from primary and secondary lymphoid 
organs but also from non-lymphoid tissues like lung and pancreas, indicating that these 
tissues contain il-7 producing non-hematopoietic cells (Fig. 3.4). Interestingly, to my 
knowledge, il-7 production from the pancreatic tissue has not been deeply investigated so 
far. However, recently published data show that blockade of IL-7R signaling by 
administration of IL-7R-specific Abs can ameliorate the phenotype of autoimmune diabetes in 
mice (125). Such systemically active therapeutic interventions impair T cell function in 
general and can therefore not be applied to patients. Since we detected il-7 expressing cells 
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in the pancreas, we propose to test more specific therapies in order to inhibit local il-7 
production by pancreatic cells. To identify selective inhibitors of il-7 production, the newly 
generated cell lines from IL-7GCDLxloxPTag mice might be particularly useful (Fig. 3.4).  
Since il-7 promoter-driven Cre expression was highly effective in thymic stroma, we focused 
on the analysis of these cells. Several studies showed high il-7 expression from thymic 
epithelium by use of IL-7 reporter mice or gene expression studies (64–66, 142). In our 
model, we additionally detected il-7 promoter-driven Cre-activity in thymic fibroblasts 
(Fig. 3.5). Furthermore, we detected reporter-expressing fibroblasts in lymph nodes but not in 
spleen, indicating that il-7 expression may vary in different SLOs or fibroblast subsets 
(Fig. 3.4). These data are similar to results from a second BAC-tg mouse in which IL-7 
regulatory elements drive expression of Cre (65). Our results indicating il-7 expression by 
fibroblasts from thymus and lymph nodes are further supported by recent reports. These 
reports include gene expression profiles from sorted stromal subpopulations and studies 
based on two newly generated knock-in mice, where the endogenous il-7 promoter drives gfp 
expression (174–177).  
Comparing the novel IL-7 reporter GFP knock-in mice to the IL-7GCDL mouse, the data 
indicate that the knock-in mice provide higher reporter sensitivity than the IL-7GCDL mouse. 
Besides differential reporter protein stability, it cannot be excluded that the BAC-derived 
promoter region does not contain all il-7 regulatory elements or that structures around the 
unknown genomic integration sites affect reporter activity. These concerns are largely 
excluded by the knock-in technology. However, the knock-in disrupts il-7 gene function and 
hence leads to lower amounts of IL-7 in these mice. This results in partial lymphopenia and 
limits the usability of these mice especially in studies involving IL-7-dependent cells like 
T cells (175). In contrast, the BAC-transgenic IL-7GCDL mouse shows normal development 
of the immune system (Fig. 3.2-3.3) and normal il-7 expression (63) emphasizing that these 
mice allow studies on the interplay of immune cells and their environment.  
In conclusion, the IL-7GCDL mouse allows identification, tracing and manipulation of 
il-7-expressing cells and will subsequently help to further unravel the function of IL-7 and of 
its producers. Better understanding of these processes will help to develop therapies to 
ameliorate progression of autoimmune disorders by e.g. inhibition of IL-7 signaling. 
Alternatively, therapies increasing IL-7 availability or triggering of its downstream molecules 
may help to drive immune reconstitution in lymphocyte-depleted patients and improve 
immune responses against chronic infections or even cancer.  
4.2 IL-7-expressing host cells decrease il-7 gene activity in response to IL-7 therapy 
One possibility to increase IL-7 availability is certainly to administer exogenous recombinant 
IL-7. However, it has been suggested that IL-7 signaling regulates IL-7 production by 
lymphoid stromal cells in vivo (91). The hypothesis is based on measurements of il-7 gene 
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activity in splenic stroma after IL-7 treatment or ablation. It implicates that the host 
counterbalances high IL-7 availability by decreasing il-7 gene expression. Since we detected 
IL-7R expression on the anatomically and developmentally very distinct intestinal epithelial 
cells (Fig. 3.6), we wanted to extend the analysis to all putatively involved tissues. Therefore 
we decided to study the effect of IL-7 application on il-7 gene activity systemically by 
determining the luciferase activity in IL-7GCDL mice. Indeed, a single injection of IL-7 
downmodulated il-7 reporter expression by 25% within 24 h (Fig. 3.6). This decline does not 
decisively interfere with systemic IL-7 levels since therapeutic doses still cause 
supraphysiological IL-7 serum levels, as shown in a human preclinical trial (134). However, 
since it was suggested that the protein mainly binds locally to extracellular matrix proteins 
(178), IL-7 therapy may alter local gradients of IL-7 availability. Whether this affects the 
homeostasis of IL-7-responsive cells has not been investigated so far. A second open 
question is whether IL-7 signaling regulates the expression of other molecules besides IL-7 
in il-7-producing stromal cells that in turn influence T cell homeostasis.  
So far, only few studies addressed the effect of IL-7 on il-7-expressing cells, partially 
because their identity has remained largely unknown. Since it was demonstrated that 
fibroblastic reticular cells in lymph nodes, (175, 176, 179), thymic fibroblasts (Fig. 3.5) and 
bone marrow mesenchymal stem cells (180) can produce il-7 mRNA, it is conceivable that 
fibroblasts from many organs have this capacity. As essential and frequent components of 
tissue structure throughout the entire body, fibroblasts constitute a vital target for IL-7 
therapy. Indeed, first reports described that IL-7 treatment inhibited transforming growth 
factor-beta (TGF-β)-induced collagen synthesis from pulmonary fibrosis fibroblasts in vitro 
and in vivo (181, 182). Under physiologic conditions, collagen can bind chemokines and thus 
create a chemokine gradient, that may affect migration of leukocytes (183) and hence T cell 
homoestasis. Besides fibroblasts, endothelial cells can likewise produce and respond to IL-7 
in vitro (184–186). Treatment of human aortic endothelial cells with IL-7 increased 
expression of monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion 
molecule-1 (ICAM-1) and VCAM-1, which enhanced recruitment of monocytes (185). 
Recently published data also show that IL-7 is produced by lymphatic endothelial cells 
(LECs) and supports their growth and function (118). Lymphatic drainage was suggested to 
contribute to peripheral tolerance by delivering self-Ag to lymph node–resident leukocytes in 
the steady state. However, LECs can also directly act as APCs by scavenging and cross-
presenting exogenous Ags. This causes dysfunctional activation of CD8+ T cells and thereby 
contributes to peripheral tolerance (187, 188). So far, it has not been investigated whether 
IL-7 therapy can alter immune responses by affecting LEC growth and function. Yet, it is 
well-accepted that lymphatic drainage of soluble Ags and migration of APCs via lymphatics 
are pivotal for initiation of protective immune responses (189, 190).  
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In conclusion, our results show that IL-7-producing cells react to IL-7 treatment, which leads 
to decreased il-7 expression in vivo. So far, we have not analyzed in detail which cell types 
react to IL-7 and which other molecules are affected by IL-7 therapy. However, fibroblasts, 
blood and lymphatic endothelial cells have already been described as putative cell types 
producing and responding to IL-7. All of these stromal cells interact with leukocytes. Hence 
IL-7 therapy may affect T cell homeostasis indirectly via its action on stromal cells.  
4.3 IL-7 therapy induces T cell-independent enlargement of the spleen 
The effect of IL-7 therapy on leukocytes was first tested in spleens of T cell-deficient hosts. 
IL-7 therapy led to an IL-7R-dependent enlargement of the spleen, which mostly consisted of 
myeloid cells (Fig. 3.7). Since myeloid cells develop independently of IL-7 in the steady state 
and myeloid cell counts do not increase in blood of IL-7-treated patients, the increased 
numbers of myeloid cells in spleen is presumably indirect and might involve processes like 
chemoattraction (104, 134, 185). Enlargement of the spleen after IL-7 therapy has also been 
detected in other studies involving T cell-competent mice and humans (134, 149). Since LIP 
and Ag-induced activation of T cells is controlled by DCs (105, 191), we also wanted to study 
whether they reacted to IL-7 therapy. DC numbers increased upon IL-7 therapy in spleens of 
Rag- mice (Fig. 3.8A). Since most mature DCs do not express the IL-7R, it is assumed that 
they do not respond to IL-7. Yet, IL-7 signaling was shown to increase DC numbers by 
driving the development of DC subsets, presumably from IL-7-dependent common lymphoid 
progenitors (104). Interestingly, the proportion of CD8- cells within the DC pool was elevated 
in PBS-treated Rag- compared to IL-7R-xRag- animals (Fig. 3.8C). This small but significant 
effect of steady-state IL-7 signaling has, to my knowledge, not been described before. It 
suggests that basal host IL-7 signaling affects the generation of these cells. In contrast, it 
was already shown that IL-7 signaling downmodulates MHC-II on DCs and this observation 
correlated with reduced LIP of CD4+ T cells (91). We extended these findings from IL-7 
signaling-deficient mice to the clinically relevant setting of IL-7 therapy (Fig. 3.8D). The fact 
that DCs from IL-7R-xRag- inherently express lower levels of MHC-II shows that other factors 
regulate its expression. Since the IL-7Rα chain is utilized by the IL-7R and the TSLPR 
(thymic stromal lymphopoietin receptor) (192), the lack of TSLPR-signaling may contribute to 
the observed phenotype. Indeed, it has already been shown that treatment of isolated DCs 
with TSLP causes MHC-II upregulation in vitro (193, 194). Thus, absence of TSLPR-
signaling in IL-7Rα- animals might be causal for the low MHC-II expression by DCs. Yet other 
indirect mechanisms cannot be excluded. Besides MHC-II expression, CD54 and CD86 were 
also downmodulated on DCs from Rag- mice after IL-7 therapy (Fig. 3.8E-F), while 
expression of CD40 and MHC-I remained unaffected (Fig. 3.8G-H). The decreased 
expression of important molecules for T cell stimulation by IL-7-treated DCs may affect their 
capacity to efficiently elicit T cell responses. On the other hand, increased DC numbers in 
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spleens of IL-7-treated Rag- mice may counterbalance the phenotypic changes and increase 
homeostatic proliferation and responsiveness to foreign Ag (105, 195). Therefore, it was 
tested whether IL-7 therapy mediates its effects on T cells via host cells including DCs. 
4.4 IL-7-responsive host cells and IL-7 therapy affect the memory formation of 
adoptively transferred T cells 
IL-7 signals in CD8+ T cells are essential for LIP (70). However, it was unknown whether IL-7 
signaling in non-T cells contributes to the modulation of LIP. To answer this question, OT-I 
T cells were transferred into Rag- and IL-7R-xRag- hosts. Based on the recovered cell 
number 3 weeks after transfer and traced frequency of divisions 5 days after transfer, OT-I 
T cells underwent LIP similarly well in both hosts, indicating that IL-7R-xRag- mice are 
suitable to separate the effects of IL-7 therapy on T cells exclusively from effects on the host 
and T cells (Fig. 3.9-3.10). IL-7 therapy increased the rate of division in both hosts equally 
well (Fig. 3.10B-C), indicating that proliferation is independent of host IL-7R-mediated signals 
and hence also independent of the DC phenotype and numbers. Interestingly, 11 days after 
transfer, OT-I T cells accumulated more in spleens of IL-7R-xRag- recipients and IL-7 therapy 
enhanced this difference (Fig. 3.11B). This host IL-7R-regulated effect was transient and not 
observed 3 weeks after transfer (Fig. 3.11D). Since some lymph nodes in IL-7R-xRag- mice 
are smaller sized or even absent (110, 112), it is possible that limited space in LNs alters 
distribution and increases OT-I T cell frequencies in spleen early after transfer. When we 
analyzed the phenotype of the OT-I T cells 3 weeks after transfer, we observed lower 
frequencies of CD62L+ TCM cells in spleens of IL-7R-competent
 Rag- recipients (Fig. 3.12A). 
Together with higher frequencies of KLRG-1+ TEM / TSLEC cells (Fig. 3.12B), our data indicate 
that homing or differentiation of adoptively transferred T cells is regulated by IL-7-responsive 
host cells. IL-7 therapy increased not only the number of T cells but also the frequency of TCM 
cells in IL-7R-competent and -deficient recipients, suggesting that IL-7 therapy enhances TCM 
cell differentiation and/or proliferation. Higher TM cell numbers were also observed in other 
studies applying IL-7 to mice and humans, but a shift towards TCM has only been observed in 
some studies (132, 133, 149, 157, 196). However, the involved signaling pathways have 
largely remained unclear. It was shown that IL-7 signaling can lead to AKT activation that is 
able to decrease FOXO1 activity and thus lower CD62L expression in T cells (94, 95, 101). 
Accordingly, strong AKT activation by high-dose IL-7 treatment leads to low CD62L levels 
(197). Remarkably, it was demonstrated that the IL-7 therapy regime used in this study 
consisting of IL-7 in a complex with an IL-7-neuralizing Ab is highly potent in vivo because it 
decreases rapid consumption of IL-7 (198). Thus, it can be considered as weak but 
persistent signal. Indeed, it was shown that this treatment actually increases FOXO1 activity 
(197). In consequence, the tightly balanced contact to IL-7 can explain why we detected 
higher frequencies of CD62L+ T cells after IL-7 therapy and why results are inconsistent in 
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this field. Similar to CD62L, also the expression of CD127 is regulated by FOXO1 (101). 
Therefore it is not surprising that CD127 expression was also elevated after 3 weeks of IL-7 
therapy (Fig. 3.12C). Yet, in contrast to CD62L, the regulation of CD127 was not affected by 
IL-7-responsive host cells. Bcl-2 expression is induced by IL-7R-signaling in T cells (81). 
Indeed, others and we detected higher Bcl-2 levels in T cells after IL-7 therapy (Fig. 3.12D) 
(133, 157). Interestingly, Bcl-2 levels were also controlled by IL-7R-competent host cells, as 
its levels were lower in T cells transferred into IL-7R+ recipients. This could be due to lower 
IL-7 levels in these mice (91). However, since host IL-7R signaling affected Bcl-2 levels even 
in the presence of IL-7 therapy, we suggest that IL-7 availability is not the main 
environmental factor controlling Bcl-2 expression. In summary, we showed that over a period 
of 3 weeks, the number and phenotype of adoptively transferred T cells was modulated by 
IL-7 therapy, which promoted the accumulation of or differentiation to TCM cells in 
lymphopenic conditions. Remarkably, this development was partially compromised in IL-7R-
competent hosts, indicating that host IL-7R signaling may counteract IL-7 signaling-induced 
processes in T cells. 
4.5 IL-7 therapy-assisted anti-tumor ATT depends on IL-7-responsive host cells  
Since the memory phenotype of T cells was influenced by host IL-7R signaling and IL-7 
therapy, we aimed to determine the T cell effector function. After short-term in vitro 
stimulation with cognate peptide, the capacity to produce IFN-γ was mildy increased in 
T cells that were transferred into IL-7R-xRag- mice (Fig. 3.12E). In IL-7-treated animals 
however, this difference was not observed. In contrast, other groups observed stronger IFN-γ 
production upon IL-7-mediated signaling both, in vitro and in vivo (102, 122, 199, 200). One 
possible explanation for this discrepancy is that in our study, the T cells were stimulated with 
high doses of Ag to determine the total response capacity. This might have masked 
differences in T cell responsiveness. Moreover, T cells were transferred into lymphopenic 
mice that already contain elevated amounts of IL-7 (91). Thus the threshold for enhancing 
IFN-γ production might have already been reached. Furthermore, long-term cytotoxic 
function of the transferred T cells was assessed by challenge of the previously IL-7-treated or 
untreated T cell recipients with the Ag-expressing tumor cell line EG7. Tumor growth was 
delayed in all therapeutic T cell-containing animals. However, the group that received IL-7 
therapy and expressed the IL-7R on host cells was significantly better protected than all 
other groups (Fig. 3.13B-C). We anticipated that IL-7 therapy would improve anti-tumor 
responses, as it promoted TCM generation which was shown to mediate protection from tumor 
growth (58, 59) and increased T cell numbers that persisted for 4 weeks in tumor-bearing 
hosts (Fig. 3.14A). Other groups also reported a beneficial effect of IL-7 administration on 
anti-tumor and anti-viral responses in preclinical models (130, 131, 201). Unexpectedly, our 
results showed that IL-7 therapy did only improve anti-tumor responses in IL-7R-competent 
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hosts, indicating that IL-7-assisted anti-tumor therapy is dependent on the IL-7-responsive 
environment. This observation is surprising because T cell numbers and phenotype 
(CD62L+KLRG-1-Bcl-2highCD127high) pointed to at least equally strong anti-tumor responses in 
IL-7R-xRag- compared to Rag- hosts (Fig. 3.11D, 3.12). However, only the IL-7R signaling-
competent Rag- mice profited from IL-7 therapy with significantly decreased tumor incidence. 
The question emerges whether T cell responses are in general impaired in IL-7R-xRag- 
compared to Rag- animals, e.g. due to developmental defects in some SLOs needed for 
initiating immune responses (117). However, tumor growth was delayed/inhibited to a similar 
extent in PBS-treated Rag- and IL-7R-xRag- mice compared to animals that had not received 
T cells (Fig. 3.13B-C), suggesting that T cell functionality was retained in IL-7R- hosts. Yet, it 
cannot be excluded that the IL-7R- environment altered tumor cell settling, growth or 
persistence. Notably, IL-7 was reported to induce proangiogenic factors, which in turn could 
facilitate nutrient supply but also entry of immune cells modulating tumor growth (202, 203). 
However, IL-7 administration during the growth phase of the EG7 tumor did not reveal any 
influence of IL-7 availability on tumor growth in our experimental system (Fig. 3.13A). Despite 
that, careful analysis of tumor growth kinetics revealed a slightly faster tumor growth rate in 
most experiments involving IL-7R-xRag- compared to Rag- hosts that had not received OT-I 
T cells (Fig. 3.13A). This suggests that the absence of IL-7R-signaling in host cells enhances 
tumor cell settling or growth. In conclusion, the presented data strongly indicate that the 
beneficial effect of IL-7 therapy on anti-tumor ATT is dependent on an IL-7R-competent host 
environment.  
4.6 IL-7-responsive host cells and IL-7 therapy affect the memory differentiation of 
adoptively transferred T cells after peptide vaccination 
Using a model of pancreatic cancer, it was shown that IL-7 therapy only promotes anti-tumor 
T cell responses when the animals were vaccinated with the cancer Ag (98). Thus, in order 
to further improve anti-tumor T cell responses, we tested the combination of IL-7 treatment 
with peptide vaccination. The model also provided the opportunity to compare the potency of 
IL-7 cytokine stimulation after strong TCR stimulation to results obtained from weakly self-
peptide-stimulated T cells undergoing LIP. 
When mice were vaccinated with the cognate peptide of OT-I T cells one day after transfer, 
higher T cell numbers were recovered from spleens and blood of Rag- compared to IL-7R-
xRag- hosts 3 weeks after immunization. Concomitant IL-7 therapy massively enhanced 
T cell accumulation in immunized Rag- animals, but surprisingly, did only mildly raise T cell 
numbers in IL-7R-xRag- hosts (Fig. 3.15B-C). This observation is in contrast to data obtained 
during LIP, were T cells expanded equally well in both hosts in response to weak self-
peptide-MHC contacts (Fig. 3.11D). These data suggest that T cell priming with a strongly 
stimulating dose of Ag is impaired in IL-7R- mice. This constraint becomes more prominent in 
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the presence of IL-7 therapy, indicating that IL-7 signaling in T cells cannot compensate for 
impaired Ag-mediated priming.  
Moreover, we analyzed the phenotypic changes that occurred in transferred T cells 3 weeks 
after peptide vaccination in the early memory phase. IL-7 therapy increased the frequency of 
CD62L+ T cells while it decreased the percentage of KLRG-1+ OT-I T cells in both hosts, 
indicating that IL-7 therapy promoted TCM cell survival / differentiation directly (Fig. 3.15D-E, 
3.16A). This effect of IL-7 therapy on Ag-experienced T cells was also reported in non-
lymphopenic mice after viral infection (133, 196). In contrast to observations from 
unimmunized mice (Fig. 3.12A), the IL-7-responsive host environment did not modulate the 
frequency of Ag-experienced CD62L+ TCM cells (Fig. 3.15D-E). Yet, it lowered the percentage 
of KLRG-1+ TSLEC / TEM cells (Fig. 3.16A). Opposing results on the regulation of KLRG-1 were 
obtained in unimmunized hosts (Fig. 3.12B), which indicates that signals mediated by weak 
vs. strong TCR stimulation together with signals from the IL-7-responsive host drive distinct 
differentiation or survival processes in T cells. Another example for the stimulation- and host-
modulated effects on T cell differentiation is the regulation of the TM-development-associated 
molecule CD127. Its levels increased on OT-I T cells in immunized IL-7-treated Rag- 
recipients (Fig. 3.15F-G), but remained low in IL-7R-xRag- mice. These data differ from 
results obtained in unimmunized animals, where CD127 regulation was independent of host 
IL-7R expression (Fig. 3.12C). Moreover, we detected decreased levels of the inhibitory 
receptor PD-1 on OT-I T cells in IL-7-treated, vaccinated Rag- hosts (Fig. 3.17D). This finding 
is supported by previously published reports (98, 204). However, IL-7 therapy did not cause 
decreased PD-1 levels on T cells in IL-7R-xRag- recipients, affirming that the IL-7-responsive 
host modulates effects of therapeutic IL-7 on T cells. In conclusion, we show that for the 
generation of therapeutic TM cells with a long-lived CD127
highKLRG-1lowPD-1lowCD62Lhigh 
phenotype, IL-7 therapy has to engage host cells. This unexpected and to my knowledge 
novel finding implies that some aspects of T cell differentiation or survival are controlled by 
the IL-7-responsive host environment. This hypothesis is supported by other observations, 
for instance: IL-7 therapy decreased T-bet levels in T cells in immunized IL-7R-competent 
and -deficient animals equally well (Fig. 3.16B). The decreased expression of T-bet together 
with increased frequency of CD62L+ cells indicates that IL-7 therapy activated FOXO1 in the 
transferred T cells (197, 205), irrespective of IL-7-responsive host cells. However, in the 
same conditions, IL-7 therapy increased Bcl-2 expression exclusively in IL-7R- hosts (Fig. 
3.16D). Together, we conclude that signals from the IL-7-responsive host environment, 
together with TCR signaling intensity, cause divergent T cell differentiation.  
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4.7 IL-7-responsive non-hematopoietic host cells are the main regulators of 
memory differentiation after peptide vaccination and IL-7 therapy 
To determine which IL-7-responsive host cells mediate the distinct effects on T cell 
expansion and differentiation, BM-chimeras were generated using Rag- and IL-7R-xRag- 
mice. To achieve highest resolution for the effects of host cells on T cells, the treatment with 
strongest differences in T cell numbers was chosen. Therefore chimeric mice were treated 
with peptide vaccination and IL-7 therapy. Equally to non-chimeric animals, higher T cell 
numbers were detected when hematopoietic and non-hematopoietic host cells were IL-7R+ 
than when both host cell populations were IL-7R- (Fig. 3.18D-E). IL-7R-expression by the 
non-hematopoietic compartment was sufficient to reconstitute T cell numbers. Furthermore, 
IL-7R expression restricted to the hematopoietic compartment resulted in low, but significantly 
higher T cell numbers than in the IL-7R- host. In conclusion, non-hematopoietic cells critically 
affect T cell expansion. To a lesser extent, hematopoietic host cells are also involved. 
Additionally, we showed that the effect on T cell accumulation is occurring systemically and 
already very prominent 6 days after immunization, indicating that the early Ag-driven 
expansion is affected by IL-7 responsive host cells (Fig. 3.18E). 
Moreover, the T cell phenotype was analyzed. CD127 expression was enhanced in presence 
of IL-7R+ host cells, weakly in hosts with hematopoietic cell-restricted IL-7R, and strongly in 
hosts with non-hematopoietic cell-restricted IL-7R expression (Fig. 3.19C). This indicates that 
mainly non-hematopoietic IL-7-responsive host cells regulate the level of CD127 expression 
on transferred T cells or their survival. We also analyzed the expression of the γc-chain 
(CD132), which pairs with CD127 to form the IL-7R heterodimer (79). Although described as 
stable or ubiquitous (75, 80), it was shown that CD132 surface levels can be modulated, for 
instance after T cell stimulation (206). We detected an inverse relationship of CD132 to 
CD127 expression (Fig. 3.19C, E) and again observed that IL-7-responsive non-
hematopoietic host cells act as main regulators of CD132 expression. What could drive this 
differential expression? IL-15 is a main regulator of memory T cell survival and self-renewal 
and its receptor contains the γc-chain (69). Hence high CD132 levels on T cells might 
facilitate IL-15 signaling. IL-15 was shown to decrease CD127 levels but increase expression 
of the anti-apoptotic molecule Bcl-2 (81, 207). Interestingly Bcl-2 expression was highest in 
T cells with lowest CD127 levels, indicating that IL-15 signaling could causally link our 
observations (Fig. 3.19C, D). Furthermore, high Bcl-2 levels correlated with high Eomes 
expression (Fig. 3.19D, F). As Eomes induces the IL-2/15Rβ-chain, CD122 (160, 208), it 
might have contributed to the suggested sensitivity of the OT-I T cells for IL-15 in IL-7R- 
animals.  
In conclusion, the data presented so far strongly indicate that IL-7 therapy acts not only on 
T cells but also on host cells. IL-7-responsive non-hematopoietic host cells majorly affect the 
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expansion and differentiation of adoptively transferred T cells that proliferated strongly in 
response to peptide vaccination and IL-7 therapy in lymphopenic conditions.  
4.8 Vaccination-assisted anti-tumor ATT depends on IL-7 responsive host cells 
We evaluated the therapeutic potential of OT-I T cells expanded in vaccinated and 
IL-7-treated IL-7R+ animals and compared them to cohorts that did not receive IL-7 therapy 
or were transferred into IL-7R- recipients. In line with data obtained in unimmunized animals 
(Fig. 3.13B), the transferred T cells delayed tumor outgrowth compared to untreated control 
mice, but the majority of immunized T cell-transferred IL-7R-xRag- mice did not control tumor 
outgrowth, irrespective of IL-7 therapy (Fig. 3.20A). In contrast, the transferred OT-I T cells 
blocked tumor growth in 50% of immunized Rag- mice, indicating that IL-7-responsive host 
cells support T cell-mediated tumor cell rejection (Fig. 3.20B). Surprisingly, the group of 
immunized, T cell transferred Rag- hosts that additionally received IL-7 therapy was less well 
protected against tumor outgrowth. These data are in contrast to results obtained with 
unimmunized mice (Fig. 3.20B vs. 3.13C), indicating that the success of IL-7 therapy-
assisted anti-tumor treatment is modulated by TCR-mediated T cell differentiation. Despite 
strong accumulation of T cells in the IL-7-treated, immunized Rag- group, these T cells did 
not sufficiently eliminate tumor cells. The reason for the impaired function is unclear, as 
T cells reisolated from spleens of mice with large tumor burden were still functional 
(Fig. 3.21G-H). T cells were also initially able to migrate to the site of tumor growth, 
recognize and kill tumor cells, as they delayed tumor outgrowth in all groups compared to 
non-T cell-transferred cohorts. Subsequently, T cells in the tumor microenvironment might 
have lost functionality or died. Alternatively, certain T cell subsets were shown to promote 
tumor growth by affecting host or tumor cells (209, 210). Hence, it is possible that 
immunization combined with IL-7 therapy led to a distinct differentiation and cytokine release 
that fostered growth of the remaining tumor cells. When comparing the phenotype of these 
T cells, we detected very low frequencies of KLRG-1+ T cells in IL-7-treated vaccinated Rag- 
hosts (Fig. 3.21C). Since KLRG-1+ cells belong to the TSLEC / TEM subset, which migrate more 
efficiently to non-lymphoid organs, they may have an advantage in detecting the s.c. injected 
tumor cells. Thus, when combined with immunization, IL-7 therapy might restrict T cell 
plasticity and inhibit conversion of memory cells to secondary, cytotoxic effector T cells that 
would eradicate tumor burden. These results show that IL-7 therapy is like a mixed blessing, 
but also demonstrate that the success of ATT against cancer is dependent on 
IL-7-responsive host cells.  
4.9 Conclusions  
To summarize, this study demonstrates that IL-7-responsive host cells can affect the 
numbers, the phenotype and anti-tumor function of adoptively transferred T cells in Rag- 
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mice. The regulatory capacity of IL-7-responsive host cells is dependent on the mode of 
T cell activation. When T cells differentiate by contact to homeostatic cytokines and self-
peptides during LIP, the IL-7R+ host does not regulate T cell numbers, but impedes 
differentiation to long-lived TCM. In this situation, IL-7 therapy promotes TCM generation and 
expands the T cells largely independent of host IL-7R engagement. When T cells 
differentiate in response to strong Ag-stimulation by peptide vaccination in lymphopenic 
conditions, T cell expansion is promoted better in the IL-7-responsive host than in IL-7R- 
T cell recipients. Additional IL-7 therapy increases T cell numbers strongest in the IL-7-
responsive environment. This host-mediated effect correlates with highly increased CD127 
expression and low frequencies of terminally differentiated KLRG-1+ cells among the 
therapeutic T cell population. In mice receiving peptide vaccination combined with IL-7 
therapy, IL-7-responsive non-hematopoietic cells mainly regulated T cell expansion and 
differentiation. To a lesser extent, hematopoietic cells also contributed. Long-term function of 
the therapeutic T cells was assessed by challenge with an Ag-expressing tumor cell line. It 
revealed that protection from tumor growth is dependent on IL-7-responsive host cells. 
Surprisingly, IL-7 therapy promoted survival of mice when the transferred T cells had only 
received weak self-Ag-mediated TCR signals, but impaired survival when mice were 
vaccinated early after transfer and T cells thereby had received strong TCR signals. In 
conclusion differential TCR signaling combined with IL-7R-mediated signals in T cells 
regulated divergent memory differentiation. Surprisingly, IL-7-responsive host cells crucially 
affected these processes and in consequence, therapeutic efficacy of the adoptively 
transferred T cells. This study extends the current knowledge of how IL-7 therapy influences 
the success of adoptive T cell therapy against cancer. It proposes to focus investigations on 
the involved non-hematopoietic host cell types and mechanisms to develop more selective 
strategies of immune modulation via host cells and thereby improving therapeutic success. 
Our knowledge about non-hematopoietic host cell - T cell interactions and their role in 
regulation of immune responses is very limited. It was recently shown that lymph node 
stromal cells inhibit proliferation of activated T cell by mechanisms involving direct cell 
contact (211). The immune-regulatory stromal cells were identified as fibroblastic reticular 
cells (FRCs) and LECs. Both cell types produce IL-7 and can also respond to it (118, 181, 
182). FRCs expand after vaccination. This process is mainly dependent on DC-induced 
trapping of naive lymphocytes (212), indicating that stromal cell - T cell interactions are 
bidirectional. We link DC frequency to IL-7 signaling as we showed that DC numbers in 
spleen are regulated by both hematopoietic and non-hematopoietic IL-7 responsive host 
cells. Interestingly, it was also shown that IL-7 therapy-induced homeostatic T cell 
proliferation was sufficient for FRC expansion (212). In light of these data and results 
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obtained in this work, we propose that IL-7 signaling links T cell to stromal cell homeostasis 
and thereby critically regulates T cell responses and the success of ATT against cancer.  
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5 Materials and methods 
5.1  Materials 
5.1.1  Equipment and software 
 
Equipment     Company 
Centrifuge Megafuge 1S-R    Heraeus-Thermo Scientific 
Centrifuge Pico 17    Heraeus-Thermo Scientific 
Flow Cytometer FACSCalibur   BD Biosciences 
Flow Cytometer Canto II    BD Biosciences 
Flow Cytometer LSR Fortessa   BD Biosciences 
Gel Dokumentation Herolab E.A.S.Y Herolab 
IVIS Imaging System Series 200   Xenogen 
Magnetic Cell Sorter AutoMACS   Miltenyi Biotech 
Mastercycler Gradient    Eppendorf  
Microscope Axioplan 200   Zeiss 
Microscope Leica DM-RE   Leica 
Microwave     Severin 
PCR Machine T3000 Thermocycler   Biometra 
qPCR Machine iCycler   Biorad 
Thermal shaker Thermomix Compact Eppendorff 
 
Software     Company 
Adobe CS6      Adobe Systems Software 
AxioVision Release 4.5    Zeiss 
FlowJo 8     TreeStar 
Living Image 2.6    Xenogen 
Prism      GraphPad Software Inc. 
SPOT Advanced    SPOT Imaging Solutions 
 
5.1.2  Reagents 
Substance     Company 
7-AAD Viability Staining Solution  BD Biosciences / Biolegend 
Agarose peqGold    PeqLab 
Biocoll      Biochrom 
Borgal      Virbac Tiergesundheit  
Colenterazine     Biosynth 
Collagen G      Biochrom 
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Collagenase D     Roche 
Collagenase P    Roche 
Crystal 5x DNA loading buffer blue   Bioline 
CFSE       Invitrogen 
D-luciferin      Synchem OHG 
DMSO      Sigma-Aldrich 
DAPI (4,6-Diamidino-2-Phenylindole ) Carl Roth 
DNase I      Roche / Sigma-Aldrich 
dNTP       Applied Biosystems / Carl Roth 
Dispase II      Roche 
Dimitridazole      Sigma-Aldrich 
Doxocyclin      Sigma-Aldrich 
DMEM      Gibco 
Easy Ladder I     Bioline 
Easycoll     Biochrom 
Epithelial growth factor   BioVision 
Ethidium Bromide    Carl Roth 
Fetal calf serum (FCS)   PAN Biotech 
G418      Carl Roth 
Gelatine 45% from cold water fish skin Sigma-Aldrich 
Golgi Plug     BD Biosciences 
Golgi Stop      BD Biosciences 
Glycerol for molecular biology  Sigma-Aldrich 
Heparin Sodium Salt    Applichem 
Hexanucleotide mix    Roche 
Hydrocortisone     Sigma-Aldrich 
Insulin, human    Sigma-Aldrich 
Interleukin-7, murine, carrier-free  eBioscience 
Ketamin (Ketavet)    Pharmacia 
LPS from E.coli serotype 0111:B4   Sigma-Aldrich 
Lymphoprep      Axis-Shield 
NaCl 0,9%      Delta Pharma 
Non-essential amino acids 100x  Gibco 
Orange G     Sigma-Aldrich / Applichem 
Platinum Taq DNA Polymerase   Invitrogen 
Penicillin / streptomycin    Gibco 
Primocin      Amaxa 
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Proteinase K      Sigma-Aldrich 
Recombinant mouse IFNγ    R&D Systems / Biolegend 
Rompun     Bayer Health Care 
RPMI 1640      Gibco/Millipore 
SIINFEKL (95%)     Biosynthan 
Sugar      supermarket 
Superscript II reverse transcriptase   Invitrogen 
TaqMan Universal PCR Master Mix   Applied Biosystems 
Tissue Tek OCT compound    Sakura Finetek 
Transferrin      Gibco 
Vectashield Mounting Medium   Vector Laboratories  
Whatman 3MM paper   Sigma-Aldrich 
 
Kit         Company 
Cytofix/Cytoperm Fixation/Permeabilization Solution Kit BD Biosciences / Biolegend 
FASER Kit-APC      Miltenyi Biotech 
Foxp3 / Transcription Factor Staining Buffer Set  eBioscience 
Rnase-Free DNase Set      Qiagen 
Rneasy Mini Kit       Qiagen 
   
Antibody Clone Company 
B220 RA3-6B2 BD Biosciences 
Bcl-2 10C4 Biolegend 
CD106 429 BD Biosciences 
CD107a 1D4B BD Biosciences / Biolegend 
CD11b MI70 Biolegend/ BD 
CD11c N418 BD Biosciences / Biolegend 
CD127 A7R34 BD Biosciences / Biolegend 
 
 
CD132 TUGm2 BD Biosciences 
CD16/CD32 Fc block 2.4G2 BD Biosciences / own production 
 
 
 
 
 
CD19 1D3 eBioscience 
CD19 6D5 Biolegend 
CD326 G8.8 BD Biosciences / Biolegend 
CD4 GK1.5 BD Biosciences 
CD4 RM4-5 Biolegend 
CD40 HM40-3 Biolegend 
CD44 IM7 BD Biosciences / eBioscience / Biolegend 
CD45 30-F11 BD Biosciences / Biolegend 
CD45.2 104 BD Biosciences / Biolegend 
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CD49b DX5 Biolegend 
CD5 53-7.3 BD Biosciences / eBioscience 
CD54  3E2 BD Biosciences 
CD62L MEL-14 BD Biosciences / Biolegend 
CD69 H1.2F3 BD Biosciences / Biolegend 
CD71 R17217 eBioscience 
CD71 R17217 Biolegend 
CD80 16-10A1 BD Biosciences / Biolegend 
CD86 GL-1 BD Biosciences / Biolegend 
CD8a 53-6.7 BD Biosciences / eBioscience / Biolegend 
CD90.1 OX7 BD Biosciences / Biolegend 
CD90.2 30H12 BD Biosciences / Biolegend 
CD90.2 53-2.1 BD Biosciences / Biolegend 
DX5 DX5 BD Biosciences 
Eomes Dan11Mag eBioscience 
gp38 8.1.1 Biolegend 
Gr1 RB6-8-C5 Biolegend 
H2kb AF6-88.5 Biolegend 
I-Ab AF6-120.1 Biolegend 
IFN-γ XMG1.2 eBioscience 
Ki-67 SolA15 eBioscience 
KLRG1 2F1 eBioscience 
IL-7 M25 BioXCell 
Ly51 BP-1 BD Biosciences 
 
PD1 (CD279) J43 eBioscience 
SV40 Ag Pab 108 BD Biosciences 
T-bet 4B10 Biolegend 
TER119 TER119 Biolegend 
TNF-α MP6-XT22 BD Biosciences 
Vα2 B20.1 BD Biosciences 
Cytokeratin 5/8 RCK102 BD Biosciences 
anti-hamster IgG  Southern Biotech / Invitrogen 
anti-rabbit IgG  Invitrogen 
 
anti-rat IgG  Invitrogen 
anti-rat IgG2a  Southern Biotech 
 
Microbeads   Clone   Isotype   Company 
α-mouse CD8α  53-6.7   Rat IgG2a, κ   Miltenyi Biotech 
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PCR primers for genotyping Sequence 
Rag1 oIMR1746 WT Forward 5’-GAG GTT CCG CTA CGA CTC TG-3’   
Rag1 oIMR3104 WT Reverse 5’-CCG GAC AAG TTT TTC ATC GT-3’   
Rag1 oIMR8162 MT Forward  5’-TGG ATG TGG AAT GTG TGC GAG-3’  
  
IL-7R 119 WT Forward  5’-CTT TTA CGA GTG AAA TGC CTA ACT C-3’  
IL-7R 120 WT Reverse  5’-CAG GTA TGA TTC AAG AAT GCA ATA CA-3’  
IL-7R 121 MT Reverse  5’-CAC GGC TAG CCA ACG CTA TGT C-3’  
 
Luciferase Forward     5’-GGC CTT TGA TAC ACA GCT CG-3’  
Luciferase Reverse    5’-ACC GTC TTG GTC TAC T TG CCT-3’  
 
Primer and probes for RNA expression analysis 
Luciferase Forward    5’-GGC CTT TGA TAC ACA GCT CG-3’  
Luciferase Reverse   5’-ACC GTC TTG GTC TAC T TG CCT-3’  
Luciferase-TaqMan probe  6-FAM-CCAAGATTATGAAGTCCGCAGTGTCATCAA-TMR  
 
TaqMan primer and probes for RNA expression analysis 
IL-7   Mm 00434291_m1   Applied Biosystems 
HPRT   Mm 00446968_m1    Applied Biosystems 
Actb  Mm 00607939_s1    Applied Biosystems 
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5.1.3  Mouse strains 
Strain name       Common name  Provider /  
          Breeding facility 
B6.SJL-Ptprca Pep3b/BoyJ     CD45.1 / WT  Charles Rivers 
B6.129S7-Rag1tm1Mom     Rag-   JAX 
B6.129S7-Rag1tm1Mom/JxB6.SJL-Ptprca Pep3b/BoyJ    
CD45.1xRag-/ Rag- FEM Berlin 
B6.129S7-Il7rtm1Imx/J     IL-7R-   JAX 
B6.129S7-Rag1tm1Mom/JxB6.129S7-Il7rtm1Imx/J IL-7R-xRag-  FEM Berlin  
IL-7GCDL      IL-7GCDL  DKFZ Heidelberg 
OT-IxB6.PL-Thy1a/Cy     OT-I   DKFZ Heidelberg 
OT-IxB6.PL-Thy1a/CyxB6.129S7-Rag1tm1Mom/J RagOT-I   FEM Berlin  
OT-IxChRLuc      ChRLuc-OT-I  T. Blankenstein 
MDC Berlin 
LoxP-Tag      LoxP-Tag  G. Willimsky  
MDC Berlin 
 
All mouse strains were on a C57BL/6 background. Mice were bred under specific pathogen-
free conditions at Charite Berlin, Campus Benjamin Franklin in the Research Institute for 
Experimental Medicine (FEM), at Max-Delbrueck-Center Berlin-Buch (MDC) or at Otto-von-
Guericke University Magdeburg in the Central Animal Laboratory (ZTL). 
 
5.1.4  Buffers and media 
(Ammonium-Chloride-Potassium) ACK solution 
 0,1 mM Na2EDTA 
10 mM KHCO3 
155 mM NH4Cl 
pH: 7,2-7,4 
 
Anesthetic Ketamin/Rompun  
Ketamin 34 mg/ml 
Rompun 2,4 mg/ml 
NaCl 0,9% 
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Antibiotics mix 1 
4 g Dimitridazole 
0,012% Borgal 
15 g sugar 
 1 l of drinking water 
 
Antibiotics mix 2 
0,2 g Doxycycline  
50 g sugar 
1 l of drinking water 
pH: 2,8-3,0 
 
Coelenterazine 
Coelenterazine ampulla (0,5mg powder in controlled atmosphere at -20°C) 
150µl DMSO solvent 
450µl PBS diluent 
Prepared freshly and used within 10 min 
 
D-luciferine  
15 mg/ml D-luciferin 
1x PBS 
Stored as 1,5ml aliquots at -20°C  
 
Epithelial cell medium 
DMEM  
10% FCS  
2 mM L-Glutamine 
1 mM Na-Pyruvate 
1x non-essential amino acids 
20 ng/ml epithelial growth factor 
6 ng/ml transferrin  
6 ng/ml insulin  
1 µg/ml hydrocortisone 
50 µM ß-Mercaptoethanol  
100 µg/ml Primocin or 100 U/ml Penicillin / 100 µg/ml Streptomycin 
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Loading buffer for PCR reactions 
0,2% w/v Orange G (practical grade) 
30% v/v Glycerol 
70% v/v H20 
 
1x PBS  
1,7 mM NaH2PO4 
6,5 mM Na2HPO4 
154 mM NaCl 
pH: 7,2-7,4 
 
1x PBS + 2 mM EDTA 
1x PBS 
2 mM EDTA 
pH: 7,2-7,4 
 
1x PBS + 2 mM EDTA + 0,5% BSA  
1x PBS + 2 mM EDTA 
0,5% BSA w/v 
pH: 7,2-7,4 
 
PBS-Heparin solution 
1x PBS 
5000 U/l Heparin 
0,03% NaN3 
 
Standard medium 
RPMI 1640 
10% FCS 
100 U/ml Penicillin / 100 µg/ml Streptomycin 
 
T cell medium  
Standard medium 
2 mM L-Glutamine 
1 mM Na-Pyruvate 
50 μM β-Mercaptoethanol 
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T cell stimulation medium  
T cell medium 
1 µg/ml SIINFEKL 
1/1000 dilution of GolgiPlug for IFN-γ and TNF-α detection 
1/1000 dilution of GolgiStop for CD107a detection (in addition to GolgiPlug) 
 
Tail Buffer  
200 mM NaCl 
100 mM Tris/HCl pH: 8,5 
5 mM EDTA 
0,2% SDS 
 
50x TAE buffer 
242 g Tris 
57 ml Acetic Acid 
100 ml 0,5 M EDTA pH: 8,0 
 
TE buffer 
10 mM Tris/HCl pH 8 
1 mM EDTA pH: 8,0 
 
Tissue digestion medium I 
RPMI 1640 
10% FCS 
100 U/ml Penicillin / 100 µg/ml Streptomycin 
1 mg/ml Collagenase D  
1 mg/ml Dispase II 
100 µg/ml DNAse I 
 
Tissue digestion medium II 
RPMI 1640 
10% FCS 
100 U/ml Penicillin / 100 µg/ml Streptomycin 
0,2 mg/ml Collagenase D  
0,2 mg/ml Dispase II 
10 µg/ml DNAse I 
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5.2  Methods 
5.2.1  Molecular biology methods 
5.2.1.1 Isolation of genomic DNA from mouse-tail biopsies 
Tail (or ear) biopsies were taken from 3-6 week old mice and frozen at -20C until DNA 
extraction. Biopsies were digested with 5 μl of Proteinase K (20 mg/ml) in 600 μl Tail Buffer 
for at least 4 hours at 56°C and 350 rpm in a thermal shaker. Digested tails were then 
centrifuged at 13800 g for 5 min. In order to precipitate the DNA, the supernatant was 
transferred into a new tube containing 600 μl of 2-propanol. The sample was inverted for at 
least 10x before the sample was centrifuged at 13800 g for 10 min. The supernatant was 
removed and then, 600 μl of 70% ethanol was added to the tube. The sample was again 
centrifuged at 13800 g for 10 min. After removal of the supernatant, the DNA pellet was 
allowed to air-dry before it was dissolved in 50-300 μl TE buffer for 1hour at 68°C and 
350 rpm using a thermal cycler. 
5.2.1.2 Genotyping of mice by polymerase chain reaction 
Transgenic and knockout mice were genotyped by polymerase chain reaction (PCR). In 
order to amplify a segment of DNA, it is first heated to denature, and separate the DNA into 
two pieces of single-stranded DNA. Next, complementary short DNA sequences called 
primers, bind to the DNA region of interest allowing the enzyme Taq polymerase to 
synthesize two new strands of DNA. The cycle of denaturing and synthesizing new DNA is 
repeated as many as 40 times, leading to more than one billion exact copies of the DNA 
segment of interest, making it easy to e.g. determine the genotype of mice. 
IL-7R- mice were generated by insertion of a neomycin resistance cassette into exon 3 of the 
IL-7Rα-chain creating a non-functional gene (151). PCR was performed using a mix of 3 
primers amplifying an 850 bp fragment from wild-type (WT) DNA and a 950 bp fragment from 
mutant DNA allowing the discrimination of IL-7R WT, heterozygous or knockout mice. The 
Rag– mouse was developed by replacement of a genomic fragment of the Rag1 gene by a 
neomycin cassette leading to a non-functional gene (213). The presence of the mutant allele 
was confirmed by PCR using 3 primers amplifying a 474 bp fragment from WT DNA and a 
530 bp fragment from mutant DNA allowing the discrimination of Rag WT, heterozygous or 
knockout mice. IL-7GCDL mice were analyzed for the presence of luciferase cDNA using 2 
transgene-specific primers amplifying a 478 bp fragment. The described fragments were 
generated from approximately 100 ng of DNA using the components and conditions 
described below: 
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 PCR Mix Luciferase Rag IL-7R 
Component Volume (µl) Volume (µl) Volume (µl) 
H2O 9,95 9,95 9,35 
10x-Puffer 2 2 2 
MgCl2 (50 mM) 2 2 2 
dNTPs (2,5 mM) 2 1 1,6 
Primer 1 (10 µM) 1 1 1 
Primer 2 (10 µM) 1 1 1 
Primer 3 (10 µM)  1 1 
Loading buffer 1 1 1 
Taq polymerase 0,05 0,05 0,05 
DNA 1 1 1 
Table 5.1: PCR master mix reagents used to amplify transgenic luciferase cDNA as well as 
wild-type and mutant Rag1 and IL-7Rα gene segments. 
PCR Luciferase Rag IL-7R 
Steps T (°C) time (s) T (°C) time (s) T (°C) time (s) 
Polymerase activation 94 120 94 120 95 180 
DNA denaturation 94 30 94 30 95 30 
Primer annealing to DNA 69,2 30 58 45 66 30 
DNA extension 72 60 72 45 72 60 
Final DNA elongation 72 300 72 120 72 300 
Final hold 10 unlimited 10 unlimited 10 unlimited 
Table 5.2: Thermal cycler settings used to amplify transgenic luciferase cDNA as well as 
wild-type and mutant Rag1 and IL-7Rα gene segments. 
5.2.1.3  Agarose gel electrophoresis 
1,5%-3% w/v agarose gels were prepared by boiling agarose with 100 ml 1x TAE buffer in a 
microwave. After cooling the agarose solution to ca. 55°C, 0,5 μg/ml Ethidium Bromide was 
added and the gel was casted. Alternatively, the gel was stained with 1 µg/ml Ethidium 
Bromide for 20 min after electrophoresis was completed. The gel was transferred to an 
electrophoresis apparatus prefilled with 1x TAE buffer. As a DNA size indicator, 5 μl of “DNA 
Ladder” (100-2000 bp range) was loaded into a lane. The gel was run at 120 V for 45 min. 
Then, the gel was analyzed under UV light.  
5.2.1.4 Preparation of total RNA and cDNA 
Cultured cells were lysed with 600 µl RLT buffer (Qiagen). The samples were homogenized 
using a 1ml syringe and a 20G needle. Total RNA was isolated by use of the Qiagen RNeasy 
Mini Kit according to the manufacturers recommendations. Genomic DNA was removed on-
column using the RNase-free DNase Set. RNA was eluted in RNase-free water and its 
concentration as well as purity was measured. For cDNA synthesis, 1 μg RNA was incubated 
35x 
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in 10 μl RNase-free water at 70°C for 10 min in a thermal cycler before addition of the cDNA 
master mix as described below: 
Component Volume (µl) 
5x RT (first strand) buffer 4 
20 mM dNTPs 1 
0,1 M DTT 2 
10x Random Hexamers 2 
Superscript II RT 1 
Table 5.3: Master mix reagents used to transcribe 1 µg RNA in 10 µl H20 into cDNA. 
cDNA synthesis  
Steps T (°C) time (min) 
RNA denaturation 
(1 µg RNA in 10 µl H20) 
70 10 
Addition of master mix 4 1-2 
Primer annealing to RNA 25 10 
cDNA synthesis 42 45 
Polymerase inactivation 99 3 
Final hold 4 unlimited 
Table 5.4: Thermal cycler temperature settings used to transcribe RNA into cDNA. 
5.2.1.5 Quantification of mRNA expression 
Quantitative PCR (qPCR) is used to analyze the amount of RNA expressed in tissues or cells 
in comparison to stably expressed RNA from a so-called housekeeping gene, whose 
expression should not change upon e.g. a treatment of interest. In principle, the same 
techniques are applied as mentioned above, however, the template is reverse transcribed 
mRNA, so-called cDNA. In this work, TaqMan-probe-based assays were used to analyze 
specific amplification products. The oligonucleotide probe contains a reporter fluorescent dye 
on the 5' end and a quencher dye on the 3' end. While the probe is intact, the proximal 
quencher dye inhibits the emission of fluorescence by the reporter dye by fluorescence 
resonance energy transfer. Since the probe is designed to bind downstream of the primer 
site, it is cleaved by the 5' nuclease activity of Taq polymerase as the primer is extended. 
The cleavage leads to the separation of the reporter dye from the quencher dye, increasing 
the reporter dye signal, which is detected in every PCR cycle. Additional reporter dye 
molecules are cleaved from their probes with each cycle, resulting in an increase in 
fluorescence intensity proportional to the amount of amplicon produced. Relative expression 
of the gene of interest was normalized to hprt or Actb (β-actin). The fold difference (as 
relative mRNA expression) was calculated by the comparative CT (cycle threshold) method, 
where the CT value is determined as the number of cycles needed to detect the first 
fluorescence signal over threshold in the logarithmic phase of fluorescence intensity growth. 
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Relative expression level: 2ΔCT 
ΔCT=CThousekeeping gene-CTgene of interest 
The TaqMan assay for il-7 and the housekeeping gene hprt or β-actin were obtained from 
Applied Biosystems. TIB MOLBIOL customized the qPCR assay for Luciferase mRNA 
quantification. The master mixes were distributed in triplicates into 96-well RT-PCR plates 
and 1µl of the cDNA sample was added per well. The qPCR components and cycle 
conditions are described below: 
Component Volume (µl) 
2x TaqMan universal PCR master mix 12,5 
DNase & Rnase-free water 10,25 
20x primers and probe mix 1,25 
Table 5.5: QPCR master mix reagents used to amplify hprt, β-actin or il-7 cDNA segments. 
RNA denaturation T (°C) time (s) 
Polymerase activation 95 600 
cDNA denaturation 95 15 
DNA extention 60 60 
Final hold 4 unlimited 
Table 5.6: Thermal cycler temperature settings used to amplify hprt, β-actin or il-7 cDNA 
segments. 
Component Volume (µl) 
H2O 10,3 
10x-Puffer 2 
MgCl2 (50 mM) 2 
dNTPs (2 mM) 1 
Primer 1 (10 µM) 1 
Primer 2 (10 µM) 1 
Probe (10 µM) 1 
BSA 10 µg/ml) 1 
Taq polymerase 0,2 
cDNA  1 
Table 5.7: QPCR master mix reagents used to amplify luciferase cDNA segments. 
Temperature (°C) Time (s) 
94 300 
94 30 
66,6 30 
72 30 
4 unlimited 
Table 5.8: Thermal cycler temperature settings used to amplify luciferase cDNA segments. 
40x  
 
40x  
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5.2.2  Cell biological methods 
5.2.2.1  Preparation of cells from different tissues 
Preparation of leukocytes from blood 
Blood was taken from the facial vein of mice, mixed with 100 µl PBS-heparin or 6 µl of 
0,5 M EDTA solution and RPMI 1640 before layering it onto Lymphoprep or Biocoll solution. 
The blood samples were then centrifuged at 600 g for 20 min at room temperature (RT) and 
without brake. Since peripheral blood mononuclear cells (PBMCs) have a lower density than 
erythrocytes, they can be separated by centrifugation on appropriate density gradient 
medium. More dense erythrocytes sediment through the medium while less dense 
mononuclear cells are retained on top. PBMCs were then collected in new tubes, washed 
with 1x PBS containing 2 mM EDTA and centrifuged at 2400 g for 5 min and used for 
labeling with Ab. Alternatively, 50-100 µl of blood mixed with EDTA was directly used for 
labeling with 50 µl of Ab mix and then erythrocytes were lysed by adding 1-2 ml of red blood 
cell lysis solution from BD Biosciences for 20 min at RT in the dark. Then cells were washed 
once with 2ml of PBS containing 2 mM EDTA and used for flow cytometric analysis. 
Preparation of single cell suspensions from spleen and lymph nodes  
The spleen as well as brachial and inguinal lymph nodes were removed and stored in 2 ml 
PBS containing 2 mM EDTA on ice. The spleen or the 4 LNs together were forced through 
metal sieves with a plunger of a 10 ml plastic syringe. With the help of a 20G needle on a 
10 ml syringe, the visible tissue lumps were further disaggregated by repeated aspiration and 
release of the suspension. The tools were washed with PBS containing 2 mM EDTA in order 
to retrieve all cells from the respective tissues. Then, the single cell suspension was 
transferred into a 15 ml tube and centrifuged at 468 g for 5 min at 4°C before resuspending 
them in 1x PBS containing 2 mM EDTA for cells from lymph nodes or lysis of erythrocyte for 
splenic cells.  
Preparation of single cell suspension from bone marrow  
The femurs of mice were removed and stored in 2 ml 1x PBS containing 2 mM EDTA on ice. 
Then, the bones were cleaned from muscle tissue and both ends were cut off in order to 
insert a 22G needle and flush out the bone marrow with 1x PBS containing 2 mM EDTA. 
Then, the cell suspension was transferred into a 15 ml tube and centrifuged at 468 g for 
5 min at 4°C before erythrocytes were lysed.  
Isolation of thymic fibroblasts and epithelial cells 
The thymus was removed from individual mice, minced and incubated in RPMI 1640 for 
20 min at RT under gentle agitation. Remaining tissue fragments were incubated with tissue 
digestion medium at 37ºC for 45 min per cycle under gentle agitation. The tissue digestion 
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medium containing the released single cells was collected in 15 ml PBS containing 
5 mM EDTA and replaced with fresh tissue digestion medium for up to 3 cycles until no 
fragments were visible anymore. The cell fractions from the digestion cycles were pooled and 
used for flow cytometric analysis or cell culture experiments. The concentration of 
Collagenase D and Dispase II was tested and 0,2-0,5 mg enzyme per ml medium 
(dependent on the tissue size) was used to isolate stroma cells with good yield, high viability 
and retained cell surface antigen expression. For the generation of cultures of fibroblasts, 
single cell suspensions were cultured in standard medium, whereas for the enrichment of 
epithelial cells, single cell suspensions were cultured in epithelial cell medium on 
Collagenase G-coated plates. Medium was replaced every 3-4 days, and cells were grown to 
70-90% confluency per passage.  
Isolation of colonic epithelial cells 
Freshly isolated colons were cut in 3 pieces and incised longitudinally for feces removal. 
Then, colons were shortly washed in 20 ml PBS containing 2 mM EDTA and subsequently 
incubated for 30 min at 37°C in 2 ml/colon tissue digestion medium II. The incubation was 
stopped by addition of 30 ml PBS containing 5 mM EDTA. Then, epithelial cells were 
detached from the colonic tissue with help of a syringe plunger. Free crypts were collected 
and incubated in 30 ml PBS containing 5 mM EDTA for 10 min at 4°C to dissociate the crypts 
into single epithelial cells. Dissociated cells were passed through a 40 μm cell strainer and 
centrifuged at 468 g for 15 min. The cell pellet was carefully suspended in 1 ml PBS 
containing 5 mM EDTA and immediately used for Ab labeling.  
5.2.2.2  Lysis of erythrocytes 
ACK lysis buffer is an iso-osmotic solution containing ammonium chloride, which causes 
rapid uptake of water into erythrocytes causing their burst. The process is far slower in 
leukocytes and therefore, erythrocytes can be removed from cells suspensions without 
harming leukocytes in a defined, short time frame. 
Cell suspensions from spleen and, where indicated from BM and blood, were resuspended 
continuously for 15 s in 2 ml of ACK lysis buffer per sample. 90 s after addition of the lysis 
buffer, 7 ml of medium was added to stop the reaction. The cells were then filtered through a 
40-70 μm cell-strainer to remove clumps and centrifuged at 468 g for 5 min. After removal of 
the supernatant, lymphocytes were suspended in 1x PBS containing 2 mM EDTA. 
5.2.2.3 Characterization of cell subsets and phenotypes by flow cytometry 
Flow cytometry allows the analysis of distinct cell populations based on their size, granularity 
and expression of different markers revealed by antibodies coupled to fluorophores. Cell 
suspensions enter a stream of fluid where each cell gets hydrodynamically focused before 
passing a laser beam. The laser beam excites the fluorophores and thus induces emission of 
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light. This light is detected and converted to an electronic signal. This signal can be amplified 
and is finally graphically presented.  
Ab-labeling of cell surface antigens 
Leucocytes were isolated from blood and lymphoid organs and approximately 1-5x106 cells 
were stained in a 1,5 ml tube or a well of a 96-well plate. Prior or simultaneously to staining 
with fluorophore-conjugated Abs, cells were incubated with anti-CD16/32 Abs to block 
unspecific binding of fluorophore-conjugated Abs by their constant region. Cells were labeled 
with a mix of fluorophore-conjugated Abs diluted in 1x PBS containing 2 mM EDTA and 
0,5% BSA. As control, cells were incubated with isotype-matched fluorophore-conjugated 
control or single Abs and / or FMO (fluorescence minus one) controls. FMO controls contain 
all Abs in a panel, except of one. It is used to identify and gate cells in the context of data 
spread due to the multiple fluorophores in a panel. After the cells were incubated with the 
fluorophore-conjugated antibodies for at least 30 min at 4°C, they were washed once with 1x 
PBS containing 2 mM EDTA and centrifuged at 698 g for 2 min for 96-well plates. To 
increase the intensity of CD127 staining on colonic epithelial cells, the FASER Kit-APC was 
used in two sequential steps according to the manufacturer’s recommendations. The cells 
were then resuspended in 50-200 μl 1x PBS + 2 mM EDTA solution and transferred into 
tubes suitable for analysis by a flow cytometer. Then, data were analyzed using Cell-Quest 
Pro software from BD Biosciences or FlowJo software from Tree Star. 
Ab-labeling of intranuclear antigens 
The cells were first incubated in an Ab mix to label cell surface molecules of interest as 
described in 5.2.2.1. Then, PBS containing 2 mM EDTA was added to each well and the 
plates were centrifuged at 698 g to remove unbound Ab mix. Next, the cell pellet was 
resuspended in 50 µl of FoxP3/Transcription Factor Fixation/Permeablization solution 
(eBioscience) and incubated for 30 min at 4°C in the dark. 200 µl of FoxP3/Transcription 
Factor Permeabilization buffer (eBioscience) was added and cells were again centrifuged at 
698 g for 2 min to remove the fixative. The cell pellets were resuspended in Ab mix diluted in 
FoxP3/Transcription Factor Permeabilization buffer and incubated for at least 45 min at 4°C 
in the dark. The unbound Ab was removed by adding 200 µl of buffer and centrifugation 
before cells were resuspended in 80-150 µl 1x PBS containing 2 mM EDTA and measured 
by flow cytometry. 
Ab-labeling of intracellular cytokines 
Intracellular cytokine staining allows the determination of relative cytokine amounts produced 
by a cell of interest. In order to detect cytokines in cells, their secretion must be inhibited by 
protein transport inhibitors e.g. brefeldin A or monensin A. The cells are then fixed and 
permeabilized to allow the fluorophore-conjugated antibodies to penetrate the cells. In order 
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to detect cytokine production, 1-3x106 splenocytes were stimulated for 6 h at 37°C in 100-
200 µl T cell stimulation medium/well in 96-well round bottom plates. Alternatively, PBMCs 
from blood were mixed with splenocytes from Rag- mice as source of APCs (one spleen for 
10 PBMC samples) and stimulated as indicated above. Cells were then centrifuged at 698 g 
for 2 min. The cell pellet was resuspended in an Ab mix to label cell surface molecules of 
interest as described above. PBS containing 2 mM EDTA was then added to each well and 
the plates were centrifuged at 698 g to remove unbound Ab mix. Next, the cell pellet was 
resuspended in 50 µl of Perm/Fix solution (BD Biosciences or Biolegend) and incubated for 
30 min at 4°C in the dark. 200 µl of 1x Perm/Wash solution (BD Biosciences or Biolegend) 
was added and cells were again centrifuged at 698 g for 2 min to remove the fixative. The 
cell pellets were resuspended in anti-cytokine Ab mix diluted in 1x Perm/Wash solution and 
incubated for at least 45 min at 4°C in the dark. The unbound Ab was removed by adding 
200 µl of 1x Perm/Wash solution and centrifugation before cells were resuspended in 
80-150 µl 1x PBS containing 2 mM EDTA and measured by flow cytometry. 
5.2.2.4 Isolation of OT-I T cells using AutoMACS 
Cells of interest can be separated from other cells by labeling them with Abs conjugated to 
magnetic beads. The cells are then run through a column in which they are exposed to a 
magnetic field. The unlabeled cells pass through while the magnetically labeled cells are 
retained within the column. Upon removal of the magnetic field, labeled cells are liberated 
and eluted from the column. 
OT-I TCR transgenic mice express the cDNA of the rearranged Vα2-Jα26 and Vβ5-Jβ2.6 
TCR-chains, which recognize the peptide SIINFEKL bound to MHC-I H-2Kb (154). Thus, all 
CD8+ T cells of these mice are reactive to the SIINFEKL peptide, a foreign peptide, which is 
derived from chicken ovalbumin. Therefore, these transgenic mice allow the study of 
cytotoxic T cell responses to a known antigen. Genotyping of OT-I and Rag-OT-I mice was 
performed on isolated PBMCs as described in 4.2.2.1. These cells were labeled with Abs 
against CD8α, Vα2, CD19, B220, CD4 and the congenic markers CD90.1, CD90.2. OT-I-tg+ 
mice were defined by expression of Vα2 on all CD8α+ cells. Additionally, Rag- OT-I-tg+ mice 
were defined by low frequencies (<5%) of CD4+ and/or CD19+ or B220+ cells. 
In order to purify OT-I T cells, single cell suspensions pooled from spleen, brachial, inguinal 
and mesenteric lymph nodes from one mouse were suspended in 0,9-0,95 ml cold 1x PBS 
containing 2mM EDTA and 0,5% BSA solution and 50-100 μl α-CD8 microbeads per mouse 
were added and incubated for 20-30 min at 4°C with occasional shaking. Then, unbound 
microbeads were removed by addition of 30 ml 1x PBS containing 2 mM EDTA and 
centrifugation at 300 g for 15 min at 4°C. The cell pellet was suspended in 2 ml / mouse 
1x PBS containing 2 mM EDTA and 0,5% BSA solution and filtered through a 40 µm cell-
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strainer. The labeled cells were separated using the “positive selection” program of the 
AutoMACS or by manual cell separation on a LS column from Miltenyi according to the 
manufacturer’s recommendations. The purity and activation state of the CD8+ OT-I T cells 
were analyzed by flow cytometry using Abs recognizing CD8, Vα2, CD44, CD62L, CD69, 
CD90.1 and CD90.2. 
5.2.2.5  Labeling of CD8+ T cells with CFSE  
After the separation of CD8+ OT-I T cells by AutoMACS, the cells were washed once with 
1x PBS containing 2 mM EDTA and centrifuged at 300 g for 10 min at 4°C. 5x107 CD8+ 
T cells / ml were incubated with 5 μM Carboxyfluorescein diacetate succinimidylester (CFSE) 
in 1x PBS for 20 min at 37°C before the reaction was stopped by addition of 1x PBS 
containing 2 mM EDTA and 5% FCS. The cells were then washed twice with 1x PBS 
containing 2 mM EDTA and 5% FCS and centrifuged at 300 g for 10 min at 4°C. 
5.2.2.6  Immunostaining 
Tissues were embedded in Tissue Tek OCT compound and snap-frozen in liquid nitrogen or 
on dry ice. 6 µm thick tissue sections were cut with the help of a microtome, air dried for 
20 min and then stored at -20°C until needed. Cells were grown on cover slips in cell culture 
dishes. After removal of the medium, coverslips were stored on glass slides at -20°C until 
needed.  
For immunostaining, cells were fixed in cold acetone/methanol (1:1) for 3 min and then 
washed with PBS 3x for 5 min each. Cells were incubated for 30 min with PBS containing 1% 
BSA / 0,2% gelatin / 1% of serum from the species where the secondary Ab was generated 
in. Cells were then incubated with primary Abs for 1 h at RT. After washing with PBS / 1% 
BSA / 0,2% gelatin 3x for 5 min each, secondary Abs were added for 45 min at RT. As 
negative controls, samples were incubated with isotype-matched control Abs or secondary 
Abs only. Cells were washed once for 5 min in PBS / 1% BSA / 0,2% gelatin and incubated 
for 5 min with 1 µg/ml DAPI in PBS. Finally, cells were washed with PBS, then with distilled 
water and allowed to air dry. Samples were covered with Vectashield Mounting Medium and 
examined using a Zeiss Axioplan 200 microscope with AxioVision Release 4.5 software or a 
Leica DM-RE microscope with SPOT Advanced software. 
5.2.3 Manipulations on laboratory mice 
5.2.3.1 Transfer of cells by tail vein injection 
Cells were prepared as described in 5.2.2.4, washed with 30 ml 1x PBS containing 
2 mM EDTA and after centrifugation at 300 g for 12 min, they were finally suspended in 
1x PBS. Cells were counted and the cell number was adjusted based on the purity of the 
preparation. 200 μl of the cell suspension were injected into the tail vein of recipient mice that 
had been shorty warmed by infrared light in order to widen the vein. 
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5.2.3.2 IL-7 therapy 
Unless otherwise stated, 1,5 µg recombinant murine IL-7 was mixed with 10 µg anti-IL-7 Ab 
M25 and incubated for 20 min at RT. The mixture was then diluted with 1x PBS to a total 
volume of 200 µl per mouse and injected i.p every 3-4 days starting one day prior to T cell 
transfer. 
5.2.3.3 Peptide vaccination 
As mentioned previously, OT-I CD8+ T cells express a transgenic TCR that recognizes the 
peptide SIINFEKL presented by the MHC-I molecule H-2Kb. SIINFEKL stock solutions were 
prepared by solving the powder in DMSO (10 mg/ml). This stock was stored at -20 °C until 
further use. In order to activate OT-I T cells in vivo, 50 μg SIINFEKL in 200 µl PBS was 
injected i.v. into recipient mice one day post T cell transfer.  
5.2.3.4 Tumor cell challenge 
E.G7-OVA (EG7) was derived in 1988 from the C57BL/6 (H-2b) mouse lymphoma cell line 
EL4 by electroporation with a plasmid that carries a complete copy of chicken ovalbumin 
(OVA) mRNA and the neomycin (G418) resistance gene (214). EG7 cells synthesize and 
secrete OVA constitutively, and thus activate OT-I T cells to kill the EG7 tumor cells. In this 
study, we have made use of the EG7 cell line to study the function of OT-I T cells in different 
hosts and treatments.  
The tumor cells were cultivated in standard medium containing 0,4 mg/ml G418 in order to 
select ova-expressing cells before transfer into recipient mice. For in vivo cell inoculation, the 
cells were centrifuged at 468 g for 5 min and 2x washed with 1x PBS containing 2 mM EDTA 
to remove bovine proteins from the cell suspension. Then, cells were resuspended in 1x PBS 
and 1x106 cells were subcutaneously injected in a volume of 100-200 µl at the flanks of mice.  
5.2.3.5 In vivo imaging by bioluminescence detection 
In order to visualize luciferase activity in live animals, BL signal detection was performed 
using the IVIS Imaging system and software (Xenogen). For all in vivo imaging experiments, 
the light absorbing black fur was removed by shaving the thorax and abdomen.  
The IL-7GCDL reporter mice express click beetle green luciferase 99 under control of the 
il-7 promoter (63). 3 mg of the luciferase substrate D-luciferin was injected i. v. into the tail 
vein of mice, which were immediately anesthetized by isofluoran inhalation and then 
transferred into the IVIS Imaging System for analysis of systemic BL intensities under 
anesthesia. For detection of BL in isolated organs, mice were injected i. v. with 3 mg 
D-luciferin 2 min prior to organ removal. Organs were collected in PBS containing 1,5 mg/ml 
D-luciferin, then transferred on Whatman paper and imaged subsequently. BL signals 
collected from organs were corrected for the background signals by subtracting the signal of 
an identically sized area of Whatman paper only.  
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The systemic abundance of OT-I T cells was determined with the help of ChRLuc-OT-I mice, 
which express the humanized sea pansy (Renilla reniformis) luciferase gene under control of 
the CAG promoter (215). In order to visualize luciferase expressing OT-I T cells in live 
animals, mice were first anesthetized by isofluoran inhalation and then retrobulbally injected 
with 100 µg of the luciferase substrate colenterazine. In vivo imaging was performed under 
anesthesia within 2 minutes post injection using the IVIS Imaging System. 
5.2.3.6 Generation of bone marrow chimeric mice 
BM was isolated from both femurs and tibia, which were shortly dipped in 70% ethanol, and 
then in PBS 2x subsequently. Bone caps were removed to access the BM. The marrow was 
flushed out of the bones with PBS containing 2 mM EDTA using a 27-gauge needle. Next, it 
was centrifuged at 468g and resuspended with a 1 ml pipette to generate a single cell 
suspension, filtered through a 40 µm cell strainer and counted. BM from one donor was used 
to reconstitute 3 recipients 6-18 hours post irradiation by tail vein injection. Recipients were 
irradiated with 7-11 Gy using a C137 source after anesthesia with 50 µl Ketamin/Rompun i.p. 
Irradiated mice received an antibiotics mix via the drinking water for 3-4 weeks ad libitum.  
5.3 Statistical analysis 
Statistical analysis and graphs were generated using Graph Pad Prism5 software. Data are 
shown as single dots or means of authentic values or as relative values with SD or SEM. To 
calculate relative values of an indicated molecule, the mean value of percentages or the MFI 
of the respective treatment group was set to one and the values of all groups were calculated 
in relation. Statistical significance was determined using the non-parametric two-tailed Mann-
Whitney, paired Student’s t test, 1- and 2-way Anova, log-rank test or Wilcoxon matched-
pairs signed rank test. Significant differences were indicated as follows: * p<0,05; ** p<0,01; 
*** p<0,001. 
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7 Abbreviations 
7-AAD  7-amino-actinomycin D 
α  anti or alpha 
Ab   antibody 
Ag   antigen 
ACK  ammonium-chloride-potassium 
Actb  beta-actin 
ATT  adoptive T cell therapy 
AKT  protein kinase B (PKB) 
APC  antigen-presenting cell 
Bcl-2  B cell lymphoma 2 
BCR  B cell receptor 
BAC  bacterial artificial chromosome 
bp   base pair 
BIM   Bcl-2-interacting mediator of cell death 
BL  bioluminescence 
BLI   bioluminescence intensity 
BM   bone marrow 
BSA  bovine serum albumin 
CCR  C-C chemokine receptor 
CFSE  carboxyfluorescein succinimidyl ester 
CEC  colonic epithelial cell 
CLP  common lymphoid progenitor 
CMP  common myeloid progenitor 
cDNA   complementary DNA 
ctrl  control 
cTEC  cortical thymic epithelial cell 
CTL   cytotoxic T lymphocyte 
DAPI   4',6-diamidino-2-phenylindole 
DC  dendritic cell 
DNA  deoxyribonucleic acid 
DMSO  Dimethylsulfoxid 
DN  double-negative 
DP  double-positive 
dNTP  deoxynucleotide triphosphate 
EDTA  ethylenediamine-N, N, N’, N’-tetraacetic acid 
Eomes  Eomesodermin 
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FCS  fetal calf serum 
FMO   fluorescence minus one 
FOXO1 forkhead box protein O1 
FRC  fibroblastic reticular cell 
FSC  forward scatter 
ɣc-chain common gamma chain 
GLUT1 glucose transporter 1 
GFP  green fluorescent protein 
hprt  hypoxanthine phosphoribosyltransferase 1 
IgG  Immunoglobulin G 
IL-7R-  Interleukin-7-receptor-deficient 
IL-7R+   Interleukin-7-receptor-competent 
i.p.  intraperitoneally 
i.v.  intravenously 
ICAM-1 intracellular adhesion molecule-1, CD54 
IFN  interferon 
IL  interleukin 
ILC  innate lymphoid cell 
IRES  internal ribosome entry site 
JAK  Janus kinase 
JAX  The Jackson Laboratory 
Klf2  Kruppel-like factor 2 
KLRG-1 killer cell lectin-like receptor subfamily G member 1 
LN  lymph node 
LEC  lymphatic endothelial cell 
LTi  lymphoid tissue inducer cell 
LIP  lymphopenia-induced proliferation 
m  murine 
MACS  magnetic-activated cell sorting 
mTOR  mammalian target of rapamycin 
MHC  major histocompatibility complex 
MHC-I  major histocompatibility complex class 1 
MHC-II major histocompatibility complex class 2 
MFI   mean fluorescence intensity 
mTEC  medullary thymic epithelial cell 
MLN  mesenteric lymph node 
mRNA  messenger RNA 
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MCL1  myeloid cell leukemia 1 
NK cell  Natural killer cell 
Neo  neomycin 
PAMP  pathogen-associated molecular pattern 
PRR  pattern-recognition receptor 
PBMC  peripheral blood mononuclear cell 
PBS  phosphate-buffered saline 
PCR  polymerase chain reaction 
PI3K  phosphoinositol 3-phosphate 
PD-1  programmed death-1 
P27KIP1 cyclin-dependent kinase inhibitor 1B 
r  recombinant 
Rag  recombination activating gene 
RNA  ribonucleic acid 
SP  single-positive 
SSC  side scatter 
STAT  signal transducer and acitvator of transcription 
SD  standard deviation 
SEM  standard error of the mean 
SLEC  short-lived effector cells 
SLO  secondary lymphoid organs 
SI  small intestine 
s.c.  subcutaneously 
TAE  Tris-Acetate-EDTA 
TCM  central memory T cells 
TEM  effector memory T cells 
TEFF  effector T cells 
TEM  effector memory T cells  
TM  memory T cells 
TN  naive T cells 
TSLEC  short-lived effector T cells 
TCR  T cell receptor 
tg  transgenic 
TE  Tris-EDTA 
TGF-β  transforming growth factor-beta 
TLR  Toll-like receptor 
TNF  tumor necrosis factor 
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TSLP  thymic stromal lymphopoietin 
VCAM-1 vascular cell adhesion molecule-1; CD106 
WT   wild-type 
